jacq personal page - To The Moon

jacq

jacq

No personal profile

45Follow

1Followers

0Topic

0Badge

2021-08-24

Ok

2 Cathie Wood Growth Stocks to Buy Now

2021-08-19

Can take a look

Surprise! Here's the Cheapest COVID Vaccine Stock on the Market Right Now

2021-08-30

To the moon

Sorry, the original content has been removed

2021-08-22

Wonder when it can come down before entering

S&P 500 hasn't fallen 5% from a peak in nearly 200 sessions--what that tells market historians

2021-08-19

Can take a look

Surprise! Here's the Cheapest COVID Vaccine Stock on the Market Right Now

2021-08-24

Ok

Oil up 2% on brighter demand outlook and Mexican outage

2021-07-28

Ok

Oil rises on U.S. fuel drawdowns despite surging coronavirus cases

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3582010429782765","uuid":"3582010429782765","gmtCreate":1618934372418,"gmtModify":1627441495577,"name":"jacq","pinyin":"jacq","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/094ef2aec6c11cb7d041045295e79e0a","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":45,"tweetSize":7,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.01.16","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.84%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.31","exceedPercentage":"60.13%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":4,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":811223241,"gmtCreate":1630328117483,"gmtModify":1676530269938,"author":{"id":"3582010429782765","authorId":"3582010429782765","name":"jacq","avatar":"https://static.tigerbbs.com/094ef2aec6c11cb7d041045295e79e0a","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582010429782765","authorIdStr":"3582010429782765"},"themes":[],"htmlText":"To the moon","listText":"To the moon","text":"To the moon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/811223241","repostId":"1199138618","repostType":4,"repost":{"id":"1199138618","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1630316356,"share":"https://ttm.financial/m/news/1199138618?lang=&edition=fundamental","pubTime":"2021-08-30 17:39","market":"us","language":"en","title":"Globalstar shares rose more than 20% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1199138618","media":"Tiger Newspress","summary":"Globalstar shares rose more than 20% in premarket trading.\nApple Inc. could partner with Globalstar ","content":"<p>Globalstar&nbsp;shares&nbsp;rose&nbsp;more&nbsp;than&nbsp;20%&nbsp;in&nbsp;premarket&nbsp;trading.</p>\n<p><img src=\"https://static.tigerbbs.com/33606a167f18f6de91abf407f2f6fa7e\" tg-width=\"896\" tg-height=\"614\" width=\"100%\" height=\"auto\">Apple Inc.&nbsp;could partner with&nbsp;Globalstar Inc.&nbsp;to bring satellite communication connectivity to the upcoming&nbsp;iPhone 13&nbsp;models, according to a note from Apple analyst&nbsp;Ming-Chi Kuo,&nbsp;Apple&nbsp;Insider&nbsp;reported.</p>\n<p>A customized version of the Qualcomm X60 baseband chip that Apple is expected to use in the iPhone 13 will support low-earth-orbit (LEO) satellite communications, Kuo reportedly said in the note.</p>\n<p>iPhone 13 users will be able to directly use Globalstar’s satellite communication services on their devices if Apple partners with the LEO satellite communication service provider, Kuo said, as per the report.</p>\n<p>Apple could also use the satellite communication feature in its upcoming Apple AR headset and the Apple Car, Kuo noted.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Globalstar shares rose more than 20% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlobalstar shares rose more than 20% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-30 17:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Globalstar&nbsp;shares&nbsp;rose&nbsp;more&nbsp;than&nbsp;20%&nbsp;in&nbsp;premarket&nbsp;trading.</p>\n<p><img src=\"https://static.tigerbbs.com/33606a167f18f6de91abf407f2f6fa7e\" tg-width=\"896\" tg-height=\"614\" width=\"100%\" height=\"auto\">Apple Inc.&nbsp;could partner with&nbsp;Globalstar Inc.&nbsp;to bring satellite communication connectivity to the upcoming&nbsp;iPhone 13&nbsp;models, according to a note from Apple analyst&nbsp;Ming-Chi Kuo,&nbsp;Apple&nbsp;Insider&nbsp;reported.</p>\n<p>A customized version of the Qualcomm X60 baseband chip that Apple is expected to use in the iPhone 13 will support low-earth-orbit (LEO) satellite communications, Kuo reportedly said in the note.</p>\n<p>iPhone 13 users will be able to directly use Globalstar’s satellite communication services on their devices if Apple partners with the LEO satellite communication service provider, Kuo said, as per the report.</p>\n<p>Apple could also use the satellite communication feature in its upcoming Apple AR headset and the Apple Car, Kuo noted.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果","GSAT":"全球星"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199138618","content_text":"Globalstar shares rose more than 20% in premarket trading.\nApple Inc. could partner with Globalstar Inc. to bring satellite communication connectivity to the upcoming iPhone 13 models, according to a note from Apple analyst Ming-Chi Kuo, Apple Insider reported.\nA customized version of the Qualcomm X60 baseband chip that Apple is expected to use in the iPhone 13 will support low-earth-orbit (LEO) satellite communications, Kuo reportedly said in the note.\niPhone 13 users will be able to directly use Globalstar’s satellite communication services on their devices if Apple partners with the LEO satellite communication service provider, Kuo said, as per the report.\nApple could also use the satellite communication feature in its upcoming Apple AR headset and the Apple Car, Kuo noted.","news_type":1},"isVote":1,"tweetType":1,"viewCount":256,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":834549909,"gmtCreate":1629815431601,"gmtModify":1676530140737,"author":{"id":"3582010429782765","authorId":"3582010429782765","name":"jacq","avatar":"https://static.tigerbbs.com/094ef2aec6c11cb7d041045295e79e0a","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582010429782765","authorIdStr":"3582010429782765"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/834549909","repostId":"1191163975","repostType":4,"repost":{"id":"1191163975","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1629814313,"share":"https://ttm.financial/m/news/1191163975?lang=&edition=fundamental","pubTime":"2021-08-24 22:11","market":"us","language":"en","title":"Oil up 2% on brighter demand outlook and Mexican outage","url":"https://stock-news.laohu8.com/highlight/detail?id=1191163975","media":"Reuters","summary":"LONDON, Aug 24 (Reuters) - Oil prices rose on Tuesday, extending sharp gains on a bullish demand out","content":"<p>LONDON, Aug 24 (Reuters) - Oil prices rose on Tuesday, extending sharp gains on a bullish demand outlook as U.S. regulators issued their first full approval for a COVID-19 vaccine and Mexico suffered a large production outage.</p>\n<p>Brent crude oil futures were up $1.50, or 2.2%, at $70.25 a barrel by 13442 GMT while U.S. West Texas Intermediate (WTI) gained $1.34, or 2%, to $66.98.</p>\n<p>Both benchmarks jumped more than 5% on Monday, helped by a weaker dollar, after marking their biggest weekly losses in more than nine months last week.</p>\n<p>Though a resurgent pandemic has fuelled health system concerns, \"economically harmful containment measures seem rather unlikely\", said Julius Baer analyst Norbert Rucker, citing the effectiveness of coronavirus vaccines.</p>\n<p>The U.S. Food and Drug Administration (FDA) on Monday issued full approval for the Pfizer/BioNTech two-dose vaccine, having authorised it for emergency use last December. Health officials hope the action will convince unvaccinated Americans that the shot is safe and effective.</p>\n<p>Analysts said that China's apparent success in fighting the spread of the Delta variant also boosted demand sentiment, with no cases of locally transmitted infections reported in latest data.</p>\n<p>Also supporting oil prices was a fire on an oil platform off Mexico on Sunday. The fire killed five workers and halted 421,000 barrels per day of production, representing about a quarter of the country's overall output.</p>\n<p>The U.S. Department of Energy on Monday said it would sell up to 20 million barrels of crude from the Strategic Petroleum Reserve (SPR) oil stocks to comply with legislation, with deliveries to take place between Oct. 1 and Dec. 15.</p>\n<p>Meanwhile, Indian refiners' crude throughput in July bounced to its highest in three months as fuel demand rebounded and buoyed prices.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Oil up 2% on brighter demand outlook and Mexican outage</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOil up 2% on brighter demand outlook and Mexican outage\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-08-24 22:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>LONDON, Aug 24 (Reuters) - Oil prices rose on Tuesday, extending sharp gains on a bullish demand outlook as U.S. regulators issued their first full approval for a COVID-19 vaccine and Mexico suffered a large production outage.</p>\n<p>Brent crude oil futures were up $1.50, or 2.2%, at $70.25 a barrel by 13442 GMT while U.S. West Texas Intermediate (WTI) gained $1.34, or 2%, to $66.98.</p>\n<p>Both benchmarks jumped more than 5% on Monday, helped by a weaker dollar, after marking their biggest weekly losses in more than nine months last week.</p>\n<p>Though a resurgent pandemic has fuelled health system concerns, \"economically harmful containment measures seem rather unlikely\", said Julius Baer analyst Norbert Rucker, citing the effectiveness of coronavirus vaccines.</p>\n<p>The U.S. Food and Drug Administration (FDA) on Monday issued full approval for the Pfizer/BioNTech two-dose vaccine, having authorised it for emergency use last December. Health officials hope the action will convince unvaccinated Americans that the shot is safe and effective.</p>\n<p>Analysts said that China's apparent success in fighting the spread of the Delta variant also boosted demand sentiment, with no cases of locally transmitted infections reported in latest data.</p>\n<p>Also supporting oil prices was a fire on an oil platform off Mexico on Sunday. The fire killed five workers and halted 421,000 barrels per day of production, representing about a quarter of the country's overall output.</p>\n<p>The U.S. Department of Energy on Monday said it would sell up to 20 million barrels of crude from the Strategic Petroleum Reserve (SPR) oil stocks to comply with legislation, with deliveries to take place between Oct. 1 and Dec. 15.</p>\n<p>Meanwhile, Indian refiners' crude throughput in July bounced to its highest in three months as fuel demand rebounded and buoyed prices.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1191163975","content_text":"LONDON, Aug 24 (Reuters) - Oil prices rose on Tuesday, extending sharp gains on a bullish demand outlook as U.S. regulators issued their first full approval for a COVID-19 vaccine and Mexico suffered a large production outage.\nBrent crude oil futures were up $1.50, or 2.2%, at $70.25 a barrel by 13442 GMT while U.S. West Texas Intermediate (WTI) gained $1.34, or 2%, to $66.98.\nBoth benchmarks jumped more than 5% on Monday, helped by a weaker dollar, after marking their biggest weekly losses in more than nine months last week.\nThough a resurgent pandemic has fuelled health system concerns, \"economically harmful containment measures seem rather unlikely\", said Julius Baer analyst Norbert Rucker, citing the effectiveness of coronavirus vaccines.\nThe U.S. Food and Drug Administration (FDA) on Monday issued full approval for the Pfizer/BioNTech two-dose vaccine, having authorised it for emergency use last December. Health officials hope the action will convince unvaccinated Americans that the shot is safe and effective.\nAnalysts said that China's apparent success in fighting the spread of the Delta variant also boosted demand sentiment, with no cases of locally transmitted infections reported in latest data.\nAlso supporting oil prices was a fire on an oil platform off Mexico on Sunday. The fire killed five workers and halted 421,000 barrels per day of production, representing about a quarter of the country's overall output.\nThe U.S. Department of Energy on Monday said it would sell up to 20 million barrels of crude from the Strategic Petroleum Reserve (SPR) oil stocks to comply with legislation, with deliveries to take place between Oct. 1 and Dec. 15.\nMeanwhile, Indian refiners' crude throughput in July bounced to its highest in three months as fuel demand rebounded and buoyed prices.","news_type":1},"isVote":1,"tweetType":1,"viewCount":212,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":834557571,"gmtCreate":1629815374793,"gmtModify":1676530140699,"author":{"id":"3582010429782765","authorId":"3582010429782765","name":"jacq","avatar":"https://static.tigerbbs.com/094ef2aec6c11cb7d041045295e79e0a","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582010429782765","authorIdStr":"3582010429782765"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/834557571","repostId":"2161308889","repostType":4,"repost":{"id":"2161308889","pubTimestamp":1629814021,"share":"https://ttm.financial/m/news/2161308889?lang=&edition=fundamental","pubTime":"2021-08-24 22:07","market":"us","language":"en","title":"2 Cathie Wood Growth Stocks to Buy Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2161308889","media":"Motley Fool","summary":"Taking tips from successful stock pickers can boost your returns.","content":"<p><a href=\"https://laohu8.com/S/BPOPM\">Popular</a> asset manager Cathie Wood continues to crush the market. Ark's <b>Next Generation Internet ETF</b> is up 41% over the past year, topping the 31% return of the <b>S&amp;P 500</b>. And among the 49 positions in the fund, <b><a href=\"https://laohu8.com/S/PYPL\">PayPal</a></b> (NASDAQ:PYPL) and <b>Unity Software</b> (NYSE:U) stand out.</p>\n<p>Both stocks have actually outperformed Ark's ETF over the past year, and both companies have strong prospects for future growth. Here's why you should consider adding shares of PayPal and Unity to your portfolio.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/37e069515a731ebbf1de034332d7865e\" tg-width=\"700\" tg-height=\"428\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>1. PayPal</h2>\n<p>PayPal is <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the best known brands in the fintech space. Its platform connects 371 million consumers with 32 million merchants around the world, enabling digital payments across websites, mobile apps, and physical retail locations. That scale gives PayPal an advantage -- consumer adoption drives merchant acceptance and vice versa, creating a network effect.</p>\n<p>To reinforce that advantage, the company is investing aggressively in its platform. For instance, PayPal launched QR Code payments last year, enabling consumers to make in-store purchases with the PayPal or Venmo mobile wallet. The company also introduced a Buy Now, Pay Later (BNPL) feature, allowing consumers to split purchases into four interest-free payments.</p>\n<p>In both cases, these new services are driving engagement. According to PayPal's data, QR Code users spend 19%&nbsp;more that the average user, and BNPL boosts payment volume by 15%&nbsp;for merchants. More importantly, these aren't PayPal's only new products and services. That list also includes support for cryptocurrency, the Venmo credit card, and business profiles on Venmo.</p>\n<p>Collectively, these growth initiatives have boosted active accounts and transactions per account. Put another way, more people are using PayPal, and people are using PayPal more frequently.</p>\n<table>\n <thead>\n  <tr>\n   <th><p>Metric</p></th>\n   <th><p>Q2 2018 (TTM)</p></th>\n   <th><p>Q2 2021 (TTM)</p></th>\n   <th><p>CAGR</p></th>\n  </tr>\n </thead>\n <tbody>\n  <tr>\n   <td width=\"156\"><p>Active accounts</p></td>\n   <td width=\"156\"><p>244 million</p></td>\n   <td width=\"156\"><p>403 million</p></td>\n   <td width=\"156\"><p>18%</p></td>\n  </tr>\n  <tr>\n   <td width=\"156\"><p>Transactions per active account</p></td>\n   <td width=\"156\"><p>35.7</p></td>\n   <td width=\"156\"><p>43.5</p></td>\n   <td width=\"156\"><p>7%</p></td>\n  </tr>\n </tbody>\n</table>\n<p>Data source: PayPal&nbsp;SEC filings. TTM = trailin-12-months. CAGR = compound annual growth rate.</p>\n<p>Over the same period, PayPal's revenue surged from $14.5 billion&nbsp;to $23.8 billion, growing at 18% year. And its operating margin expanded 330 basis points, reaching 18.1% in Q2 2021. This showcases the company's operating leverage, meaning it's becoming more efficient as it scales.</p>\n<p>Looking ahead, PayPal is well positioned to maintain that momentum. During the Q2 earnings call, CEO Dan Schulman announced the pending launch of a new mobile wallet. According to Schulman, this \"super app\" will initially feature high-yield savings accounts, bill pay features, and messaging capabilities, as well as all the old functionality. But each wallet will also be unique, relying on artificial intelligence to create personalized deals and offers.</p>\n<p>In total, PayPal plans to add 25 new capabilities&nbsp;to the super app in the coming quarters, and Schulman expressed confidence in its ability to boost engagement. That's why now looks like a good time to buy this growth stock.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f75654d58655d77a85e1d04db052c62b\" tg-width=\"700\" tg-height=\"393\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>2. Unity Software</h2>\n<p>Unity's business plays into several big trends: interactive video games, augmented reality (AR), and virtual reality (VR). Its platform helps creators build immersive, real-time 3D content, then monetize that content across smartphones, personal computers, gaming consoles, and AR/VR devices. More specifically, Unity offers two distinct software products: Create Solutions and Operate Solutions.</p>\n<p>Create Solutions is a subscription-based product, providing developers with tools to create, edit, and run content across Windows, Mac, iOS, Android, and major gaming consoles. And Operate Solutions is a revenue-sharing product, enabling developers to monetize content through digital ads and in-app purchases. Collectively, these two products allow Unity to generate recurring revenue, and grow alongside its clients.</p>\n<p>Last year, an average of 2.7 billion&nbsp;monthly active users engaged with content that was created or operated with Unity, up 63%&nbsp;from 2019. And applications built on Unity averaged 5 billion downloads per month, up 41%. In short, Unity has achieved incredible scale -- and the company is still growing quickly.</p>\n<table>\n <thead>\n  <tr>\n   <th><p>Metric</p></th>\n   <th><p>Q2 2018 (TTM)</p></th>\n   <th><p>Q2 2021 (TTM)</p></th>\n   <th><p>CAGR</p></th>\n  </tr>\n </thead>\n <tbody>\n  <tr>\n   <td width=\"156\"><p>Revenue</p></td>\n   <td width=\"156\"><p>$464.5 million</p></td>\n   <td width=\"156\"><p>$929.5 million</p></td>\n   <td width=\"156\"><p>26%</p></td>\n  </tr>\n </tbody>\n</table>\n<p>Data source: Unity SEC filings, Ycharts. TTM = trailing-12-months. CAGR = compound annual growth rate.</p>\n<p>Going forward, Unity still has plenty of room to grow its business. Of course, its platform is a natural fit for game developers -- 94 out of the top 100 game studios are Unity customers&nbsp;-- but the company is also gaining traction in industries like architecture and filmmaking. And during the most recent quarter, Unity added three new automakers, an eyewear retailer, and an appliance manufacturer to its list of clients.</p>\n<p>Currently, management puts its market opportunity at $29 billion, but that number is expected to climb as new opportunities arise across gaming, AR/VR, and other industries. That's why this growth stock looks like a smart investment.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Cathie Wood Growth Stocks to Buy Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Cathie Wood Growth Stocks to Buy Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-24 22:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/24/cathie-wood-growth-stocks-to-buy-now-unity-paypal/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Popular asset manager Cathie Wood continues to crush the market. Ark's Next Generation Internet ETF is up 41% over the past year, topping the 31% return of the S&P 500. And among the 49 positions in ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/24/cathie-wood-growth-stocks-to-buy-now-unity-paypal/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PYPL":"PayPal","U":"Unity Software Inc."},"source_url":"https://www.fool.com/investing/2021/08/24/cathie-wood-growth-stocks-to-buy-now-unity-paypal/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2161308889","content_text":"Popular asset manager Cathie Wood continues to crush the market. Ark's Next Generation Internet ETF is up 41% over the past year, topping the 31% return of the S&P 500. And among the 49 positions in the fund, PayPal (NASDAQ:PYPL) and Unity Software (NYSE:U) stand out.\nBoth stocks have actually outperformed Ark's ETF over the past year, and both companies have strong prospects for future growth. Here's why you should consider adding shares of PayPal and Unity to your portfolio.\nImage source: Getty Images.\n1. PayPal\nPayPal is one of the best known brands in the fintech space. Its platform connects 371 million consumers with 32 million merchants around the world, enabling digital payments across websites, mobile apps, and physical retail locations. That scale gives PayPal an advantage -- consumer adoption drives merchant acceptance and vice versa, creating a network effect.\nTo reinforce that advantage, the company is investing aggressively in its platform. For instance, PayPal launched QR Code payments last year, enabling consumers to make in-store purchases with the PayPal or Venmo mobile wallet. The company also introduced a Buy Now, Pay Later (BNPL) feature, allowing consumers to split purchases into four interest-free payments.\nIn both cases, these new services are driving engagement. According to PayPal's data, QR Code users spend 19% more that the average user, and BNPL boosts payment volume by 15% for merchants. More importantly, these aren't PayPal's only new products and services. That list also includes support for cryptocurrency, the Venmo credit card, and business profiles on Venmo.\nCollectively, these growth initiatives have boosted active accounts and transactions per account. Put another way, more people are using PayPal, and people are using PayPal more frequently.\n\n\n\nMetric\nQ2 2018 (TTM)\nQ2 2021 (TTM)\nCAGR\n\n\n\n\nActive accounts\n244 million\n403 million\n18%\n\n\nTransactions per active account\n35.7\n43.5\n7%\n\n\n\nData source: PayPal SEC filings. TTM = trailin-12-months. CAGR = compound annual growth rate.\nOver the same period, PayPal's revenue surged from $14.5 billion to $23.8 billion, growing at 18% year. And its operating margin expanded 330 basis points, reaching 18.1% in Q2 2021. This showcases the company's operating leverage, meaning it's becoming more efficient as it scales.\nLooking ahead, PayPal is well positioned to maintain that momentum. During the Q2 earnings call, CEO Dan Schulman announced the pending launch of a new mobile wallet. According to Schulman, this \"super app\" will initially feature high-yield savings accounts, bill pay features, and messaging capabilities, as well as all the old functionality. But each wallet will also be unique, relying on artificial intelligence to create personalized deals and offers.\nIn total, PayPal plans to add 25 new capabilities to the super app in the coming quarters, and Schulman expressed confidence in its ability to boost engagement. That's why now looks like a good time to buy this growth stock.\nImage source: Getty Images.\n2. Unity Software\nUnity's business plays into several big trends: interactive video games, augmented reality (AR), and virtual reality (VR). Its platform helps creators build immersive, real-time 3D content, then monetize that content across smartphones, personal computers, gaming consoles, and AR/VR devices. More specifically, Unity offers two distinct software products: Create Solutions and Operate Solutions.\nCreate Solutions is a subscription-based product, providing developers with tools to create, edit, and run content across Windows, Mac, iOS, Android, and major gaming consoles. And Operate Solutions is a revenue-sharing product, enabling developers to monetize content through digital ads and in-app purchases. Collectively, these two products allow Unity to generate recurring revenue, and grow alongside its clients.\nLast year, an average of 2.7 billion monthly active users engaged with content that was created or operated with Unity, up 63% from 2019. And applications built on Unity averaged 5 billion downloads per month, up 41%. In short, Unity has achieved incredible scale -- and the company is still growing quickly.\n\n\n\nMetric\nQ2 2018 (TTM)\nQ2 2021 (TTM)\nCAGR\n\n\n\n\nRevenue\n$464.5 million\n$929.5 million\n26%\n\n\n\nData source: Unity SEC filings, Ycharts. TTM = trailing-12-months. CAGR = compound annual growth rate.\nGoing forward, Unity still has plenty of room to grow its business. Of course, its platform is a natural fit for game developers -- 94 out of the top 100 game studios are Unity customers -- but the company is also gaining traction in industries like architecture and filmmaking. And during the most recent quarter, Unity added three new automakers, an eyewear retailer, and an appliance manufacturer to its list of clients.\nCurrently, management puts its market opportunity at $29 billion, but that number is expected to climb as new opportunities arise across gaming, AR/VR, and other industries. That's why this growth stock looks like a smart investment.","news_type":1},"isVote":1,"tweetType":1,"viewCount":372,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":832134649,"gmtCreate":1629597728081,"gmtModify":1676530075663,"author":{"id":"3582010429782765","authorId":"3582010429782765","name":"jacq","avatar":"https://static.tigerbbs.com/094ef2aec6c11cb7d041045295e79e0a","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582010429782765","authorIdStr":"3582010429782765"},"themes":[],"htmlText":"Wonder when it can come down before entering&nbsp;","listText":"Wonder when it can come down before entering&nbsp;","text":"Wonder when it can come down before entering","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/832134649","repostId":"2161745814","repostType":4,"repost":{"id":"2161745814","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1629493200,"share":"https://ttm.financial/m/news/2161745814?lang=&edition=fundamental","pubTime":"2021-08-21 05:00","market":"us","language":"en","title":"S&P 500 hasn't fallen 5% from a peak in nearly 200 sessions--what that tells market historians","url":"https://stock-news.laohu8.com/highlight/detail?id=2161745814","media":"Dow Jones","summary":"It is an unbearable lightness of being for the S&P 500 index.\nThe broad-market measure of a basket o","content":"<p>It is an unbearable lightness of being for the S&amp;P 500 index.</p>\n<p>The broad-market measure of a basket of 500 U.S. stocks has been preternaturally resistant to pullbacks of late, despite concerns about the spread of the highly transmissible delta variant of COVID-19 and worries that the Federal Reserve’s strategy to reduce its bond purchases may be ill-timed.</p>\n<p>Yet, the S&amp;P 500 indexSPX,+0.81%has seen a largely uninterrupted ascent to such a degree that Friday marked the 200th session without a drawdown of 5% or more from a recent peak, making the current stretch of levitation the longest such since 2016, when the market went 404 sessions without falling by at least 5% peak to trough.</p>\n<p><img src=\"https://static.tigerbbs.com/d5d7a23827730d58001a0b40420acd79\" tg-width=\"981\" tg-height=\"437\" width=\"100%\" height=\"auto\">It is extremely rare for the market to enjoy such a period of relative effervescence. Indeed, such lengthy stretches without a 5% pullback or better have occurred on only eight occasions in the S&amp;P 500 index, the attached table shows.</p>\n<p>There clearly are reasons why the market is clambering higher in the recovery from COVID, set againsta daunting wall of worry. Investors are jockeying between areas of the market that are expected to boost revenue and profit faster than the rest of the pack and those that are beaten down and might benefit from a fuller economic rebound from coronavirus.</p>\n<p>Buying on Monday helped the Dow Jones Industrial AverageDJIA,+0.65%and the S&amp;P 500 indexSPX,+0.81%produce their 35th and 49th record all-time closing highs of 2021, respectively. Meanwhile, the Nasdaq Composite IndexCOMP,+1.19%stands a little over 2.5% from its record high put in on Aug. 5.</p>\n<p>There is, of course, a sense that the party for stocks can’t last forever.</p>\n<p>So, how does the market tend to perform in period after such a protracted bullish run?</p>\n<p>The data set is very small but the S&amp;P 500 has mostly climbed on a median basis, falling 1.2% in the following year but producing a median gain of 17.6% in a two-year period and 55% in the ensuing five-year period. The mean average return is better, showing a gain of 6.5%, 27.4% and 64%, respectively.</p>\n<p><img src=\"https://static.tigerbbs.com/d556c67fc01e330a57abb4c65802c29d\" tg-width=\"964\" tg-height=\"626\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>S&P 500 hasn't fallen 5% from a peak in nearly 200 sessions--what that tells market historians</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nS&P 500 hasn't fallen 5% from a peak in nearly 200 sessions--what that tells market historians\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-08-21 05:00</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>It is an unbearable lightness of being for the S&amp;P 500 index.</p>\n<p>The broad-market measure of a basket of 500 U.S. stocks has been preternaturally resistant to pullbacks of late, despite concerns about the spread of the highly transmissible delta variant of COVID-19 and worries that the Federal Reserve’s strategy to reduce its bond purchases may be ill-timed.</p>\n<p>Yet, the S&amp;P 500 indexSPX,+0.81%has seen a largely uninterrupted ascent to such a degree that Friday marked the 200th session without a drawdown of 5% or more from a recent peak, making the current stretch of levitation the longest such since 2016, when the market went 404 sessions without falling by at least 5% peak to trough.</p>\n<p><img src=\"https://static.tigerbbs.com/d5d7a23827730d58001a0b40420acd79\" tg-width=\"981\" tg-height=\"437\" width=\"100%\" height=\"auto\">It is extremely rare for the market to enjoy such a period of relative effervescence. Indeed, such lengthy stretches without a 5% pullback or better have occurred on only eight occasions in the S&amp;P 500 index, the attached table shows.</p>\n<p>There clearly are reasons why the market is clambering higher in the recovery from COVID, set againsta daunting wall of worry. Investors are jockeying between areas of the market that are expected to boost revenue and profit faster than the rest of the pack and those that are beaten down and might benefit from a fuller economic rebound from coronavirus.</p>\n<p>Buying on Monday helped the Dow Jones Industrial AverageDJIA,+0.65%and the S&amp;P 500 indexSPX,+0.81%produce their 35th and 49th record all-time closing highs of 2021, respectively. Meanwhile, the Nasdaq Composite IndexCOMP,+1.19%stands a little over 2.5% from its record high put in on Aug. 5.</p>\n<p>There is, of course, a sense that the party for stocks can’t last forever.</p>\n<p>So, how does the market tend to perform in period after such a protracted bullish run?</p>\n<p>The data set is very small but the S&amp;P 500 has mostly climbed on a median basis, falling 1.2% in the following year but producing a median gain of 17.6% in a two-year period and 55% in the ensuing five-year period. The mean average return is better, showing a gain of 6.5%, 27.4% and 64%, respectively.</p>\n<p><img src=\"https://static.tigerbbs.com/d556c67fc01e330a57abb4c65802c29d\" tg-width=\"964\" tg-height=\"626\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"161125":"标普500","513500":"标普500ETF","OEF":"标普100指数ETF-iShares","SPXU":"三倍做空标普500ETF","SDS":"两倍做空标普500ETF","UPRO":"三倍做多标普500ETF","IVV":"标普500指数ETF","OEX":"标普100",".SPX":"S&P 500 Index","SSO":"两倍做多标普500ETF","SH":"标普500反向ETF","SPY":"标普500ETF"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2161745814","content_text":"It is an unbearable lightness of being for the S&P 500 index.\nThe broad-market measure of a basket of 500 U.S. stocks has been preternaturally resistant to pullbacks of late, despite concerns about the spread of the highly transmissible delta variant of COVID-19 and worries that the Federal Reserve’s strategy to reduce its bond purchases may be ill-timed.\nYet, the S&P 500 indexSPX,+0.81%has seen a largely uninterrupted ascent to such a degree that Friday marked the 200th session without a drawdown of 5% or more from a recent peak, making the current stretch of levitation the longest such since 2016, when the market went 404 sessions without falling by at least 5% peak to trough.\nIt is extremely rare for the market to enjoy such a period of relative effervescence. Indeed, such lengthy stretches without a 5% pullback or better have occurred on only eight occasions in the S&P 500 index, the attached table shows.\nThere clearly are reasons why the market is clambering higher in the recovery from COVID, set againsta daunting wall of worry. Investors are jockeying between areas of the market that are expected to boost revenue and profit faster than the rest of the pack and those that are beaten down and might benefit from a fuller economic rebound from coronavirus.\nBuying on Monday helped the Dow Jones Industrial AverageDJIA,+0.65%and the S&P 500 indexSPX,+0.81%produce their 35th and 49th record all-time closing highs of 2021, respectively. Meanwhile, the Nasdaq Composite IndexCOMP,+1.19%stands a little over 2.5% from its record high put in on Aug. 5.\nThere is, of course, a sense that the party for stocks can’t last forever.\nSo, how does the market tend to perform in period after such a protracted bullish run?\nThe data set is very small but the S&P 500 has mostly climbed on a median basis, falling 1.2% in the following year but producing a median gain of 17.6% in a two-year period and 55% in the ensuing five-year period. The mean average return is better, showing a gain of 6.5%, 27.4% and 64%, respectively.","news_type":1},"isVote":1,"tweetType":1,"viewCount":115,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":838389583,"gmtCreate":1629374211142,"gmtModify":1676530019487,"author":{"id":"3582010429782765","authorId":"3582010429782765","name":"jacq","avatar":"https://static.tigerbbs.com/094ef2aec6c11cb7d041045295e79e0a","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582010429782765","authorIdStr":"3582010429782765"},"themes":[],"htmlText":"Can take a look&nbsp;","listText":"Can take a look&nbsp;","text":"Can take a look","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/838389583","repostId":"2160765013","repostType":4,"repost":{"id":"2160765013","pubTimestamp":1629373500,"share":"https://ttm.financial/m/news/2160765013?lang=&edition=fundamental","pubTime":"2021-08-19 19:45","market":"us","language":"en","title":"Surprise! Here's the Cheapest COVID Vaccine Stock on the Market Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2160765013","media":"Motley Fool","summary":"The least expensive COVID-19 vaccine stock right now isn't one of the leaders in the market -- at least not yet.","content":"<p>Valuation, schmaluation. That seems to be the view of many investors right now when it comes to <b>Moderna</b> (NASDAQ:MRNA). The vaccine maker's market cap is close to $150 billion, and approached $200 billion just a few days ago.</p>\n<p>However, not all vaccine stocks are priced so richly as Moderna. What's the cheapest COVID-19 vaccine stock on the market right now? There's <a href=\"https://laohu8.com/S/AONE.U\">one</a> surprising winner.</p>\n<p><img src=\"https://static.tigerbbs.com/afc8ec91516cee88af3be9e9d44737bf\" tg-width=\"700\" tg-height=\"393\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>A surprising winner</h3>\n<p>There are five companies trading on major U.S. stock exchanges that currently have COVID-19 vaccines on the market somewhere in the world. They include Moderna, <b>Pfizer</b> (NYSE:PFE) and <b>BioNTech</b> (NASDAQ:BNTX), and <b>Johnson &amp; Johnson</b> (NYSE:JNJ), all of which have coronavirus vaccines currently available in the U.S. <b>AstraZeneca</b> (NASDAQ:AZN), which has a vaccine authorized in several countries outside the U.S., is also traded on a U.S. exchange.</p>\n<p>In addition, there are a handful of other publicly traded companies that are evaluating COVID-19 vaccine candidates in late-stage clinical studies. <b>Novavax</b> (NASDAQ:NVAX) expects to file for Emergency Use Authorization (EUA) for its candidate, NVX-CoV2373, later this year. Others include big pharma companies <b>GlaxoSmithKline</b> (NYSE:GSK) and <b><a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a></b> (NASDAQ:SNY), along with the smaller biotechs <b>CureVac</b> (NASDAQ:CVAC) and <b>Dynavax</b> (NASDAQ:DVAX).</p>\n<p>We can't use earnings-based metrics to compare the valuations of these vaccine stocks for a simple reason: Several of them aren't yet profitable. However, to get a good sense of how the stocks stack up against each other, we can use forward price-to-sales (P/S) multiples. I used the current prices and the consensus analyst estimates of 2022 revenue for each stock to determine the cheapest of the bunch:</p>\n<table>\n <thead>\n  <tr>\n   <th>Stock</th>\n   <th><p><b>Forward P/S</b></p></th>\n  </tr>\n </thead>\n <tbody>\n  <tr>\n   <td>GlaxoSmithKline</td>\n   <td>2.1</td>\n  </tr>\n  <tr>\n   <td>Sanofi</td>\n   <td>2.7</td>\n  </tr>\n  <tr>\n   <td>Dynavax</td>\n   <td>2.8</td>\n  </tr>\n  <tr>\n   <td>Novavax</td>\n   <td>3.5</td>\n  </tr>\n  <tr>\n   <td>Pfizer</td>\n   <td>4.1</td>\n  </tr>\n  <tr>\n   <td>AstraZeneca</td>\n   <td>4.3</td>\n  </tr>\n  <tr>\n   <td>Johnson &amp; Johnson</td>\n   <td>4.7</td>\n  </tr>\n  <tr>\n   <td>BioNTech</td>\n   <td>6.4</td>\n  </tr>\n  <tr>\n   <td>CureVac</td>\n   <td>6.7</td>\n  </tr>\n  <tr>\n   <td>Moderna</td>\n   <td>8.5</td>\n  </tr>\n </tbody>\n</table>\n<p>Data source: Yahoo! Finance. Calculations by author.</p>\n<p>GlaxoSmithKline was easily the least expensive vaccine stock of all, based on forward P/S ratios. The big drugmaker isn't as frequently mentioned in discussions about COVID-19 vaccines because it wasn't one of the first to advance a program into clinical testing.</p>\n<p>However, GSK's adjuvant technology is being used in several COVID-19 vaccine candidates, and three of those are currently in late-stage testing.</p>\n<h3>Cheap for a reason, but maybe just a season</h3>\n<p>There's a good reason why GlaxoSmithKline stock is cheap: The company has underperformed compared to its peers. GSK projects that its adjusted earnings per share will fall this year by a \"mid-to-high single-digit percentage.\"</p>\n<p>GlaxoSmithKline CFO Iain Mackay noted in the company's Q2 conference call that the earnings guidance excludes any potential contribution from its COVID-19 programs. The drugmaker posted solid second-quarter results. However, Mackay said, \"There remains potential for further pandemic disruption, and we believe it's premature to change guidance.\"</p>\n<p>Still, there's a case to be made that GSK stock won't be as cheap as it currently is for too much longer. The anticipated spinoff of the company's consumer health unit next year will give GSK around $11 billion to invest in its core pharmaceutical and vaccine business. The company also expects a strong sales rebound for its shingles vaccine Shingrix in 2022.</p>\n<h3>Better bargains</h3>\n<p>There are two vaccine stocks that I think could be better bargains than GlaxoSmithKline -- Dynavax and Novavax. Sure, they both have higher forward P/S multiples than GSK, but they should also have stronger growth prospects.</p>\n<p>Everything seems to be going Dynavax's way these days. In the second quarter, the company reported record sales for its hepatitis B vaccine Heplisav-B, and the vaccine appears to be on track to become the standard of care in the U.S. I expect a solid European launch for Heplisav-B as well.</p>\n<p>Dynavax also has a major growth driver with its CpG 1018 adjuvant. Several companies are developing COVID-19 vaccines using the powerful adjuvant, which is also used in Heplisav-B.</p>\n<p>I think that Novavax is another stock with plenty of room to run. The key for the company is to win EUAs for NVX-CoV2373. Although the vaccine has experienced delays in its EUA submissions, its phase 3 data should be enough to win regulatory green lights, as long as the company can show that it can manufacture it with consistent quality.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Surprise! Here's the Cheapest COVID Vaccine Stock on the Market Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSurprise! Here's the Cheapest COVID Vaccine Stock on the Market Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-19 19:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/19/the-cheapest-covid-vaccine-stock-on-the-market-rig/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Valuation, schmaluation. That seems to be the view of many investors right now when it comes to Moderna (NASDAQ:MRNA). The vaccine maker's market cap is close to $150 billion, and approached $200 ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/19/the-cheapest-covid-vaccine-stock-on-the-market-rig/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/08/19/the-cheapest-covid-vaccine-stock-on-the-market-rig/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2160765013","content_text":"Valuation, schmaluation. That seems to be the view of many investors right now when it comes to Moderna (NASDAQ:MRNA). The vaccine maker's market cap is close to $150 billion, and approached $200 billion just a few days ago.\nHowever, not all vaccine stocks are priced so richly as Moderna. What's the cheapest COVID-19 vaccine stock on the market right now? There's one surprising winner.\n\nImage source: Getty Images.\nA surprising winner\nThere are five companies trading on major U.S. stock exchanges that currently have COVID-19 vaccines on the market somewhere in the world. They include Moderna, Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX), and Johnson & Johnson (NYSE:JNJ), all of which have coronavirus vaccines currently available in the U.S. AstraZeneca (NASDAQ:AZN), which has a vaccine authorized in several countries outside the U.S., is also traded on a U.S. exchange.\nIn addition, there are a handful of other publicly traded companies that are evaluating COVID-19 vaccine candidates in late-stage clinical studies. Novavax (NASDAQ:NVAX) expects to file for Emergency Use Authorization (EUA) for its candidate, NVX-CoV2373, later this year. Others include big pharma companies GlaxoSmithKline (NYSE:GSK) and Sanofi (NASDAQ:SNY), along with the smaller biotechs CureVac (NASDAQ:CVAC) and Dynavax (NASDAQ:DVAX).\nWe can't use earnings-based metrics to compare the valuations of these vaccine stocks for a simple reason: Several of them aren't yet profitable. However, to get a good sense of how the stocks stack up against each other, we can use forward price-to-sales (P/S) multiples. I used the current prices and the consensus analyst estimates of 2022 revenue for each stock to determine the cheapest of the bunch:\n\n\n\nStock\nForward P/S\n\n\n\n\nGlaxoSmithKline\n2.1\n\n\nSanofi\n2.7\n\n\nDynavax\n2.8\n\n\nNovavax\n3.5\n\n\nPfizer\n4.1\n\n\nAstraZeneca\n4.3\n\n\nJohnson & Johnson\n4.7\n\n\nBioNTech\n6.4\n\n\nCureVac\n6.7\n\n\nModerna\n8.5\n\n\n\nData source: Yahoo! Finance. Calculations by author.\nGlaxoSmithKline was easily the least expensive vaccine stock of all, based on forward P/S ratios. The big drugmaker isn't as frequently mentioned in discussions about COVID-19 vaccines because it wasn't one of the first to advance a program into clinical testing.\nHowever, GSK's adjuvant technology is being used in several COVID-19 vaccine candidates, and three of those are currently in late-stage testing.\nCheap for a reason, but maybe just a season\nThere's a good reason why GlaxoSmithKline stock is cheap: The company has underperformed compared to its peers. GSK projects that its adjusted earnings per share will fall this year by a \"mid-to-high single-digit percentage.\"\nGlaxoSmithKline CFO Iain Mackay noted in the company's Q2 conference call that the earnings guidance excludes any potential contribution from its COVID-19 programs. The drugmaker posted solid second-quarter results. However, Mackay said, \"There remains potential for further pandemic disruption, and we believe it's premature to change guidance.\"\nStill, there's a case to be made that GSK stock won't be as cheap as it currently is for too much longer. The anticipated spinoff of the company's consumer health unit next year will give GSK around $11 billion to invest in its core pharmaceutical and vaccine business. The company also expects a strong sales rebound for its shingles vaccine Shingrix in 2022.\nBetter bargains\nThere are two vaccine stocks that I think could be better bargains than GlaxoSmithKline -- Dynavax and Novavax. Sure, they both have higher forward P/S multiples than GSK, but they should also have stronger growth prospects.\nEverything seems to be going Dynavax's way these days. In the second quarter, the company reported record sales for its hepatitis B vaccine Heplisav-B, and the vaccine appears to be on track to become the standard of care in the U.S. I expect a solid European launch for Heplisav-B as well.\nDynavax also has a major growth driver with its CpG 1018 adjuvant. Several companies are developing COVID-19 vaccines using the powerful adjuvant, which is also used in Heplisav-B.\nI think that Novavax is another stock with plenty of room to run. The key for the company is to win EUAs for NVX-CoV2373. Although the vaccine has experienced delays in its EUA submissions, its phase 3 data should be enough to win regulatory green lights, as long as the company can show that it can manufacture it with consistent quality.","news_type":1},"isVote":1,"tweetType":1,"viewCount":118,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":838389814,"gmtCreate":1629374191738,"gmtModify":1676530019518,"author":{"id":"3582010429782765","authorId":"3582010429782765","name":"jacq","avatar":"https://static.tigerbbs.com/094ef2aec6c11cb7d041045295e79e0a","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582010429782765","authorIdStr":"3582010429782765"},"themes":[],"htmlText":"Can take a look&nbsp;","listText":"Can take a look&nbsp;","text":"Can take a look","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/838389814","repostId":"2160765013","repostType":4,"repost":{"id":"2160765013","pubTimestamp":1629373500,"share":"https://ttm.financial/m/news/2160765013?lang=&edition=fundamental","pubTime":"2021-08-19 19:45","market":"us","language":"en","title":"Surprise! Here's the Cheapest COVID Vaccine Stock on the Market Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2160765013","media":"Motley Fool","summary":"The least expensive COVID-19 vaccine stock right now isn't one of the leaders in the market -- at least not yet.","content":"<p>Valuation, schmaluation. That seems to be the view of many investors right now when it comes to <b>Moderna</b> (NASDAQ:MRNA). The vaccine maker's market cap is close to $150 billion, and approached $200 billion just a few days ago.</p>\n<p>However, not all vaccine stocks are priced so richly as Moderna. What's the cheapest COVID-19 vaccine stock on the market right now? There's <a href=\"https://laohu8.com/S/AONE.U\">one</a> surprising winner.</p>\n<p><img src=\"https://static.tigerbbs.com/afc8ec91516cee88af3be9e9d44737bf\" tg-width=\"700\" tg-height=\"393\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>A surprising winner</h3>\n<p>There are five companies trading on major U.S. stock exchanges that currently have COVID-19 vaccines on the market somewhere in the world. They include Moderna, <b>Pfizer</b> (NYSE:PFE) and <b>BioNTech</b> (NASDAQ:BNTX), and <b>Johnson &amp; Johnson</b> (NYSE:JNJ), all of which have coronavirus vaccines currently available in the U.S. <b>AstraZeneca</b> (NASDAQ:AZN), which has a vaccine authorized in several countries outside the U.S., is also traded on a U.S. exchange.</p>\n<p>In addition, there are a handful of other publicly traded companies that are evaluating COVID-19 vaccine candidates in late-stage clinical studies. <b>Novavax</b> (NASDAQ:NVAX) expects to file for Emergency Use Authorization (EUA) for its candidate, NVX-CoV2373, later this year. Others include big pharma companies <b>GlaxoSmithKline</b> (NYSE:GSK) and <b><a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a></b> (NASDAQ:SNY), along with the smaller biotechs <b>CureVac</b> (NASDAQ:CVAC) and <b>Dynavax</b> (NASDAQ:DVAX).</p>\n<p>We can't use earnings-based metrics to compare the valuations of these vaccine stocks for a simple reason: Several of them aren't yet profitable. However, to get a good sense of how the stocks stack up against each other, we can use forward price-to-sales (P/S) multiples. I used the current prices and the consensus analyst estimates of 2022 revenue for each stock to determine the cheapest of the bunch:</p>\n<table>\n <thead>\n  <tr>\n   <th>Stock</th>\n   <th><p><b>Forward P/S</b></p></th>\n  </tr>\n </thead>\n <tbody>\n  <tr>\n   <td>GlaxoSmithKline</td>\n   <td>2.1</td>\n  </tr>\n  <tr>\n   <td>Sanofi</td>\n   <td>2.7</td>\n  </tr>\n  <tr>\n   <td>Dynavax</td>\n   <td>2.8</td>\n  </tr>\n  <tr>\n   <td>Novavax</td>\n   <td>3.5</td>\n  </tr>\n  <tr>\n   <td>Pfizer</td>\n   <td>4.1</td>\n  </tr>\n  <tr>\n   <td>AstraZeneca</td>\n   <td>4.3</td>\n  </tr>\n  <tr>\n   <td>Johnson &amp; Johnson</td>\n   <td>4.7</td>\n  </tr>\n  <tr>\n   <td>BioNTech</td>\n   <td>6.4</td>\n  </tr>\n  <tr>\n   <td>CureVac</td>\n   <td>6.7</td>\n  </tr>\n  <tr>\n   <td>Moderna</td>\n   <td>8.5</td>\n  </tr>\n </tbody>\n</table>\n<p>Data source: Yahoo! Finance. Calculations by author.</p>\n<p>GlaxoSmithKline was easily the least expensive vaccine stock of all, based on forward P/S ratios. The big drugmaker isn't as frequently mentioned in discussions about COVID-19 vaccines because it wasn't one of the first to advance a program into clinical testing.</p>\n<p>However, GSK's adjuvant technology is being used in several COVID-19 vaccine candidates, and three of those are currently in late-stage testing.</p>\n<h3>Cheap for a reason, but maybe just a season</h3>\n<p>There's a good reason why GlaxoSmithKline stock is cheap: The company has underperformed compared to its peers. GSK projects that its adjusted earnings per share will fall this year by a \"mid-to-high single-digit percentage.\"</p>\n<p>GlaxoSmithKline CFO Iain Mackay noted in the company's Q2 conference call that the earnings guidance excludes any potential contribution from its COVID-19 programs. The drugmaker posted solid second-quarter results. However, Mackay said, \"There remains potential for further pandemic disruption, and we believe it's premature to change guidance.\"</p>\n<p>Still, there's a case to be made that GSK stock won't be as cheap as it currently is for too much longer. The anticipated spinoff of the company's consumer health unit next year will give GSK around $11 billion to invest in its core pharmaceutical and vaccine business. The company also expects a strong sales rebound for its shingles vaccine Shingrix in 2022.</p>\n<h3>Better bargains</h3>\n<p>There are two vaccine stocks that I think could be better bargains than GlaxoSmithKline -- Dynavax and Novavax. Sure, they both have higher forward P/S multiples than GSK, but they should also have stronger growth prospects.</p>\n<p>Everything seems to be going Dynavax's way these days. In the second quarter, the company reported record sales for its hepatitis B vaccine Heplisav-B, and the vaccine appears to be on track to become the standard of care in the U.S. I expect a solid European launch for Heplisav-B as well.</p>\n<p>Dynavax also has a major growth driver with its CpG 1018 adjuvant. Several companies are developing COVID-19 vaccines using the powerful adjuvant, which is also used in Heplisav-B.</p>\n<p>I think that Novavax is another stock with plenty of room to run. The key for the company is to win EUAs for NVX-CoV2373. Although the vaccine has experienced delays in its EUA submissions, its phase 3 data should be enough to win regulatory green lights, as long as the company can show that it can manufacture it with consistent quality.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Surprise! Here's the Cheapest COVID Vaccine Stock on the Market Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSurprise! Here's the Cheapest COVID Vaccine Stock on the Market Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-19 19:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/19/the-cheapest-covid-vaccine-stock-on-the-market-rig/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Valuation, schmaluation. That seems to be the view of many investors right now when it comes to Moderna (NASDAQ:MRNA). The vaccine maker's market cap is close to $150 billion, and approached $200 ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/19/the-cheapest-covid-vaccine-stock-on-the-market-rig/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/08/19/the-cheapest-covid-vaccine-stock-on-the-market-rig/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2160765013","content_text":"Valuation, schmaluation. That seems to be the view of many investors right now when it comes to Moderna (NASDAQ:MRNA). The vaccine maker's market cap is close to $150 billion, and approached $200 billion just a few days ago.\nHowever, not all vaccine stocks are priced so richly as Moderna. What's the cheapest COVID-19 vaccine stock on the market right now? There's one surprising winner.\n\nImage source: Getty Images.\nA surprising winner\nThere are five companies trading on major U.S. stock exchanges that currently have COVID-19 vaccines on the market somewhere in the world. They include Moderna, Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX), and Johnson & Johnson (NYSE:JNJ), all of which have coronavirus vaccines currently available in the U.S. AstraZeneca (NASDAQ:AZN), which has a vaccine authorized in several countries outside the U.S., is also traded on a U.S. exchange.\nIn addition, there are a handful of other publicly traded companies that are evaluating COVID-19 vaccine candidates in late-stage clinical studies. Novavax (NASDAQ:NVAX) expects to file for Emergency Use Authorization (EUA) for its candidate, NVX-CoV2373, later this year. Others include big pharma companies GlaxoSmithKline (NYSE:GSK) and Sanofi (NASDAQ:SNY), along with the smaller biotechs CureVac (NASDAQ:CVAC) and Dynavax (NASDAQ:DVAX).\nWe can't use earnings-based metrics to compare the valuations of these vaccine stocks for a simple reason: Several of them aren't yet profitable. However, to get a good sense of how the stocks stack up against each other, we can use forward price-to-sales (P/S) multiples. I used the current prices and the consensus analyst estimates of 2022 revenue for each stock to determine the cheapest of the bunch:\n\n\n\nStock\nForward P/S\n\n\n\n\nGlaxoSmithKline\n2.1\n\n\nSanofi\n2.7\n\n\nDynavax\n2.8\n\n\nNovavax\n3.5\n\n\nPfizer\n4.1\n\n\nAstraZeneca\n4.3\n\n\nJohnson & Johnson\n4.7\n\n\nBioNTech\n6.4\n\n\nCureVac\n6.7\n\n\nModerna\n8.5\n\n\n\nData source: Yahoo! Finance. Calculations by author.\nGlaxoSmithKline was easily the least expensive vaccine stock of all, based on forward P/S ratios. The big drugmaker isn't as frequently mentioned in discussions about COVID-19 vaccines because it wasn't one of the first to advance a program into clinical testing.\nHowever, GSK's adjuvant technology is being used in several COVID-19 vaccine candidates, and three of those are currently in late-stage testing.\nCheap for a reason, but maybe just a season\nThere's a good reason why GlaxoSmithKline stock is cheap: The company has underperformed compared to its peers. GSK projects that its adjusted earnings per share will fall this year by a \"mid-to-high single-digit percentage.\"\nGlaxoSmithKline CFO Iain Mackay noted in the company's Q2 conference call that the earnings guidance excludes any potential contribution from its COVID-19 programs. The drugmaker posted solid second-quarter results. However, Mackay said, \"There remains potential for further pandemic disruption, and we believe it's premature to change guidance.\"\nStill, there's a case to be made that GSK stock won't be as cheap as it currently is for too much longer. The anticipated spinoff of the company's consumer health unit next year will give GSK around $11 billion to invest in its core pharmaceutical and vaccine business. The company also expects a strong sales rebound for its shingles vaccine Shingrix in 2022.\nBetter bargains\nThere are two vaccine stocks that I think could be better bargains than GlaxoSmithKline -- Dynavax and Novavax. Sure, they both have higher forward P/S multiples than GSK, but they should also have stronger growth prospects.\nEverything seems to be going Dynavax's way these days. In the second quarter, the company reported record sales for its hepatitis B vaccine Heplisav-B, and the vaccine appears to be on track to become the standard of care in the U.S. I expect a solid European launch for Heplisav-B as well.\nDynavax also has a major growth driver with its CpG 1018 adjuvant. Several companies are developing COVID-19 vaccines using the powerful adjuvant, which is also used in Heplisav-B.\nI think that Novavax is another stock with plenty of room to run. The key for the company is to win EUAs for NVX-CoV2373. Although the vaccine has experienced delays in its EUA submissions, its phase 3 data should be enough to win regulatory green lights, as long as the company can show that it can manufacture it with consistent quality.","news_type":1},"isVote":1,"tweetType":1,"viewCount":213,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":803289054,"gmtCreate":1627441321578,"gmtModify":1703490033060,"author":{"id":"3582010429782765","authorId":"3582010429782765","name":"jacq","avatar":"https://static.tigerbbs.com/094ef2aec6c11cb7d041045295e79e0a","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582010429782765","authorIdStr":"3582010429782765"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/803289054","repostId":"2154432059","repostType":4,"repost":{"id":"2154432059","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1627435733,"share":"https://ttm.financial/m/news/2154432059?lang=&edition=fundamental","pubTime":"2021-07-28 09:28","market":"fut","language":"en","title":"Oil rises on U.S. fuel drawdowns despite surging coronavirus cases","url":"https://stock-news.laohu8.com/highlight/detail?id=2154432059","media":"Reuters","summary":"MELBOURNE, July 28 (Reuters) - Oil prices climbed on Wednesday after industry data showed U.S. crude","content":"<p>MELBOURNE, July 28 (Reuters) - Oil prices climbed on Wednesday after industry data showed U.S. crude and product inventories fell more sharply than expected last week, reinforcing expectations that demand will outstrip supply growth even amid a surge in COVID-19 cases.</p>\n<p>U.S. West Texas Intermediate <a href=\"https://laohu8.com/S/WTI\">$(WTI)$</a> crude futures rose 43 cents, or 0.6%, to $72.08 a barrel at 0119 GMT, reversing Tuesday's 0.4% decline.</p>\n<p>Brent crude futures rose 38 cents, or 0.5%, to $74.86 a barrel, after shedding 2 cents on Tuesday in the first decline in six days.</p>\n<p>Data from the American Petroleum Institute industry group showed U.S. crude stocks fell by 4.7 million barrels for the week ended July 23, gasoline inventories dropped by 6.2 million barrels and distillate stocks were down 1.9 million barrels, according to two market sources, who spoke on condition of anonymity.</p>\n<p>That compared with analysts' expectations for a 2.9 million fall in crude stocks, following a surprise rise in crude inventories the previous week in what was the first increase since May.</p>\n<p>Traders are awaiting data from the U.S. Energy Information Administration <a href=\"https://laohu8.com/S/EIA\">$(EIA)$</a> on Wednesday to confirm the drop in stocks.</p>\n<p>\"Most energy traders were unfazed by last week's build, so expectations should be high for the EIA crude oil inventory data to confirm inventories resumed their declining trend,\" OANDA analyst Edward Moya said in a research note.</p>\n<p>On gasoline stocks, analysts had expected a 900,000 barrel decline drop in the week to July 23.</p>\n<p>\"The U.S. is still in peak driving season and everyone is trying to make the most of this summer,\" Moya said.</p>\n<p>Fuel demand expectations are undented by soaring cases of the highly infectious Delta variant of the coronavirus in the United States, where the seven-day average for new cases has risen to 57,126. That is about a quarter of the pandemic peak.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Oil rises on U.S. fuel drawdowns despite surging coronavirus cases</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOil rises on U.S. fuel drawdowns despite surging coronavirus cases\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-07-28 09:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>MELBOURNE, July 28 (Reuters) - Oil prices climbed on Wednesday after industry data showed U.S. crude and product inventories fell more sharply than expected last week, reinforcing expectations that demand will outstrip supply growth even amid a surge in COVID-19 cases.</p>\n<p>U.S. West Texas Intermediate <a href=\"https://laohu8.com/S/WTI\">$(WTI)$</a> crude futures rose 43 cents, or 0.6%, to $72.08 a barrel at 0119 GMT, reversing Tuesday's 0.4% decline.</p>\n<p>Brent crude futures rose 38 cents, or 0.5%, to $74.86 a barrel, after shedding 2 cents on Tuesday in the first decline in six days.</p>\n<p>Data from the American Petroleum Institute industry group showed U.S. crude stocks fell by 4.7 million barrels for the week ended July 23, gasoline inventories dropped by 6.2 million barrels and distillate stocks were down 1.9 million barrels, according to two market sources, who spoke on condition of anonymity.</p>\n<p>That compared with analysts' expectations for a 2.9 million fall in crude stocks, following a surprise rise in crude inventories the previous week in what was the first increase since May.</p>\n<p>Traders are awaiting data from the U.S. Energy Information Administration <a href=\"https://laohu8.com/S/EIA\">$(EIA)$</a> on Wednesday to confirm the drop in stocks.</p>\n<p>\"Most energy traders were unfazed by last week's build, so expectations should be high for the EIA crude oil inventory data to confirm inventories resumed their declining trend,\" OANDA analyst Edward Moya said in a research note.</p>\n<p>On gasoline stocks, analysts had expected a 900,000 barrel decline drop in the week to July 23.</p>\n<p>\"The U.S. is still in peak driving season and everyone is trying to make the most of this summer,\" Moya said.</p>\n<p>Fuel demand expectations are undented by soaring cases of the highly infectious Delta variant of the coronavirus in the United States, where the seven-day average for new cases has risen to 57,126. That is about a quarter of the pandemic peak.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SCO":"二倍做空彭博原油指数ETF","DUG":"二倍做空石油与天然气ETF(ProShares)","USO":"美国原油ETF","DWT":"三倍做空原油ETN","DDG":"ProShares做空石油与天然气ETF","UCO":"二倍做多彭博原油ETF"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2154432059","content_text":"MELBOURNE, July 28 (Reuters) - Oil prices climbed on Wednesday after industry data showed U.S. crude and product inventories fell more sharply than expected last week, reinforcing expectations that demand will outstrip supply growth even amid a surge in COVID-19 cases.\nU.S. West Texas Intermediate $(WTI)$ crude futures rose 43 cents, or 0.6%, to $72.08 a barrel at 0119 GMT, reversing Tuesday's 0.4% decline.\nBrent crude futures rose 38 cents, or 0.5%, to $74.86 a barrel, after shedding 2 cents on Tuesday in the first decline in six days.\nData from the American Petroleum Institute industry group showed U.S. crude stocks fell by 4.7 million barrels for the week ended July 23, gasoline inventories dropped by 6.2 million barrels and distillate stocks were down 1.9 million barrels, according to two market sources, who spoke on condition of anonymity.\nThat compared with analysts' expectations for a 2.9 million fall in crude stocks, following a surprise rise in crude inventories the previous week in what was the first increase since May.\nTraders are awaiting data from the U.S. Energy Information Administration $(EIA)$ on Wednesday to confirm the drop in stocks.\n\"Most energy traders were unfazed by last week's build, so expectations should be high for the EIA crude oil inventory data to confirm inventories resumed their declining trend,\" OANDA analyst Edward Moya said in a research note.\nOn gasoline stocks, analysts had expected a 900,000 barrel decline drop in the week to July 23.\n\"The U.S. is still in peak driving season and everyone is trying to make the most of this summer,\" Moya said.\nFuel demand expectations are undented by soaring cases of the highly infectious Delta variant of the coronavirus in the United States, where the seven-day average for new cases has risen to 57,126. That is about a quarter of the pandemic peak.","news_type":1},"isVote":1,"tweetType":1,"viewCount":196,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":834557571,"gmtCreate":1629815374793,"gmtModify":1676530140699,"author":{"id":"3582010429782765","authorId":"3582010429782765","name":"jacq","avatar":"https://static.tigerbbs.com/094ef2aec6c11cb7d041045295e79e0a","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582010429782765","authorIdStr":"3582010429782765"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/834557571","repostId":"2161308889","repostType":4,"repost":{"id":"2161308889","pubTimestamp":1629814021,"share":"https://ttm.financial/m/news/2161308889?lang=&edition=fundamental","pubTime":"2021-08-24 22:07","market":"us","language":"en","title":"2 Cathie Wood Growth Stocks to Buy Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2161308889","media":"Motley Fool","summary":"Taking tips from successful stock pickers can boost your returns.","content":"<p><a href=\"https://laohu8.com/S/BPOPM\">Popular</a> asset manager Cathie Wood continues to crush the market. Ark's <b>Next Generation Internet ETF</b> is up 41% over the past year, topping the 31% return of the <b>S&amp;P 500</b>. And among the 49 positions in the fund, <b><a href=\"https://laohu8.com/S/PYPL\">PayPal</a></b> (NASDAQ:PYPL) and <b>Unity Software</b> (NYSE:U) stand out.</p>\n<p>Both stocks have actually outperformed Ark's ETF over the past year, and both companies have strong prospects for future growth. Here's why you should consider adding shares of PayPal and Unity to your portfolio.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/37e069515a731ebbf1de034332d7865e\" tg-width=\"700\" tg-height=\"428\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>1. PayPal</h2>\n<p>PayPal is <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the best known brands in the fintech space. Its platform connects 371 million consumers with 32 million merchants around the world, enabling digital payments across websites, mobile apps, and physical retail locations. That scale gives PayPal an advantage -- consumer adoption drives merchant acceptance and vice versa, creating a network effect.</p>\n<p>To reinforce that advantage, the company is investing aggressively in its platform. For instance, PayPal launched QR Code payments last year, enabling consumers to make in-store purchases with the PayPal or Venmo mobile wallet. The company also introduced a Buy Now, Pay Later (BNPL) feature, allowing consumers to split purchases into four interest-free payments.</p>\n<p>In both cases, these new services are driving engagement. According to PayPal's data, QR Code users spend 19%&nbsp;more that the average user, and BNPL boosts payment volume by 15%&nbsp;for merchants. More importantly, these aren't PayPal's only new products and services. That list also includes support for cryptocurrency, the Venmo credit card, and business profiles on Venmo.</p>\n<p>Collectively, these growth initiatives have boosted active accounts and transactions per account. Put another way, more people are using PayPal, and people are using PayPal more frequently.</p>\n<table>\n <thead>\n  <tr>\n   <th><p>Metric</p></th>\n   <th><p>Q2 2018 (TTM)</p></th>\n   <th><p>Q2 2021 (TTM)</p></th>\n   <th><p>CAGR</p></th>\n  </tr>\n </thead>\n <tbody>\n  <tr>\n   <td width=\"156\"><p>Active accounts</p></td>\n   <td width=\"156\"><p>244 million</p></td>\n   <td width=\"156\"><p>403 million</p></td>\n   <td width=\"156\"><p>18%</p></td>\n  </tr>\n  <tr>\n   <td width=\"156\"><p>Transactions per active account</p></td>\n   <td width=\"156\"><p>35.7</p></td>\n   <td width=\"156\"><p>43.5</p></td>\n   <td width=\"156\"><p>7%</p></td>\n  </tr>\n </tbody>\n</table>\n<p>Data source: PayPal&nbsp;SEC filings. TTM = trailin-12-months. CAGR = compound annual growth rate.</p>\n<p>Over the same period, PayPal's revenue surged from $14.5 billion&nbsp;to $23.8 billion, growing at 18% year. And its operating margin expanded 330 basis points, reaching 18.1% in Q2 2021. This showcases the company's operating leverage, meaning it's becoming more efficient as it scales.</p>\n<p>Looking ahead, PayPal is well positioned to maintain that momentum. During the Q2 earnings call, CEO Dan Schulman announced the pending launch of a new mobile wallet. According to Schulman, this \"super app\" will initially feature high-yield savings accounts, bill pay features, and messaging capabilities, as well as all the old functionality. But each wallet will also be unique, relying on artificial intelligence to create personalized deals and offers.</p>\n<p>In total, PayPal plans to add 25 new capabilities&nbsp;to the super app in the coming quarters, and Schulman expressed confidence in its ability to boost engagement. That's why now looks like a good time to buy this growth stock.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f75654d58655d77a85e1d04db052c62b\" tg-width=\"700\" tg-height=\"393\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>2. Unity Software</h2>\n<p>Unity's business plays into several big trends: interactive video games, augmented reality (AR), and virtual reality (VR). Its platform helps creators build immersive, real-time 3D content, then monetize that content across smartphones, personal computers, gaming consoles, and AR/VR devices. More specifically, Unity offers two distinct software products: Create Solutions and Operate Solutions.</p>\n<p>Create Solutions is a subscription-based product, providing developers with tools to create, edit, and run content across Windows, Mac, iOS, Android, and major gaming consoles. And Operate Solutions is a revenue-sharing product, enabling developers to monetize content through digital ads and in-app purchases. Collectively, these two products allow Unity to generate recurring revenue, and grow alongside its clients.</p>\n<p>Last year, an average of 2.7 billion&nbsp;monthly active users engaged with content that was created or operated with Unity, up 63%&nbsp;from 2019. And applications built on Unity averaged 5 billion downloads per month, up 41%. In short, Unity has achieved incredible scale -- and the company is still growing quickly.</p>\n<table>\n <thead>\n  <tr>\n   <th><p>Metric</p></th>\n   <th><p>Q2 2018 (TTM)</p></th>\n   <th><p>Q2 2021 (TTM)</p></th>\n   <th><p>CAGR</p></th>\n  </tr>\n </thead>\n <tbody>\n  <tr>\n   <td width=\"156\"><p>Revenue</p></td>\n   <td width=\"156\"><p>$464.5 million</p></td>\n   <td width=\"156\"><p>$929.5 million</p></td>\n   <td width=\"156\"><p>26%</p></td>\n  </tr>\n </tbody>\n</table>\n<p>Data source: Unity SEC filings, Ycharts. TTM = trailing-12-months. CAGR = compound annual growth rate.</p>\n<p>Going forward, Unity still has plenty of room to grow its business. Of course, its platform is a natural fit for game developers -- 94 out of the top 100 game studios are Unity customers&nbsp;-- but the company is also gaining traction in industries like architecture and filmmaking. And during the most recent quarter, Unity added three new automakers, an eyewear retailer, and an appliance manufacturer to its list of clients.</p>\n<p>Currently, management puts its market opportunity at $29 billion, but that number is expected to climb as new opportunities arise across gaming, AR/VR, and other industries. That's why this growth stock looks like a smart investment.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Cathie Wood Growth Stocks to Buy Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Cathie Wood Growth Stocks to Buy Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-24 22:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/24/cathie-wood-growth-stocks-to-buy-now-unity-paypal/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Popular asset manager Cathie Wood continues to crush the market. Ark's Next Generation Internet ETF is up 41% over the past year, topping the 31% return of the S&P 500. And among the 49 positions in ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/24/cathie-wood-growth-stocks-to-buy-now-unity-paypal/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PYPL":"PayPal","U":"Unity Software Inc."},"source_url":"https://www.fool.com/investing/2021/08/24/cathie-wood-growth-stocks-to-buy-now-unity-paypal/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2161308889","content_text":"Popular asset manager Cathie Wood continues to crush the market. Ark's Next Generation Internet ETF is up 41% over the past year, topping the 31% return of the S&P 500. And among the 49 positions in the fund, PayPal (NASDAQ:PYPL) and Unity Software (NYSE:U) stand out.\nBoth stocks have actually outperformed Ark's ETF over the past year, and both companies have strong prospects for future growth. Here's why you should consider adding shares of PayPal and Unity to your portfolio.\nImage source: Getty Images.\n1. PayPal\nPayPal is one of the best known brands in the fintech space. Its platform connects 371 million consumers with 32 million merchants around the world, enabling digital payments across websites, mobile apps, and physical retail locations. That scale gives PayPal an advantage -- consumer adoption drives merchant acceptance and vice versa, creating a network effect.\nTo reinforce that advantage, the company is investing aggressively in its platform. For instance, PayPal launched QR Code payments last year, enabling consumers to make in-store purchases with the PayPal or Venmo mobile wallet. The company also introduced a Buy Now, Pay Later (BNPL) feature, allowing consumers to split purchases into four interest-free payments.\nIn both cases, these new services are driving engagement. According to PayPal's data, QR Code users spend 19% more that the average user, and BNPL boosts payment volume by 15% for merchants. More importantly, these aren't PayPal's only new products and services. That list also includes support for cryptocurrency, the Venmo credit card, and business profiles on Venmo.\nCollectively, these growth initiatives have boosted active accounts and transactions per account. Put another way, more people are using PayPal, and people are using PayPal more frequently.\n\n\n\nMetric\nQ2 2018 (TTM)\nQ2 2021 (TTM)\nCAGR\n\n\n\n\nActive accounts\n244 million\n403 million\n18%\n\n\nTransactions per active account\n35.7\n43.5\n7%\n\n\n\nData source: PayPal SEC filings. TTM = trailin-12-months. CAGR = compound annual growth rate.\nOver the same period, PayPal's revenue surged from $14.5 billion to $23.8 billion, growing at 18% year. And its operating margin expanded 330 basis points, reaching 18.1% in Q2 2021. This showcases the company's operating leverage, meaning it's becoming more efficient as it scales.\nLooking ahead, PayPal is well positioned to maintain that momentum. During the Q2 earnings call, CEO Dan Schulman announced the pending launch of a new mobile wallet. According to Schulman, this \"super app\" will initially feature high-yield savings accounts, bill pay features, and messaging capabilities, as well as all the old functionality. But each wallet will also be unique, relying on artificial intelligence to create personalized deals and offers.\nIn total, PayPal plans to add 25 new capabilities to the super app in the coming quarters, and Schulman expressed confidence in its ability to boost engagement. That's why now looks like a good time to buy this growth stock.\nImage source: Getty Images.\n2. Unity Software\nUnity's business plays into several big trends: interactive video games, augmented reality (AR), and virtual reality (VR). Its platform helps creators build immersive, real-time 3D content, then monetize that content across smartphones, personal computers, gaming consoles, and AR/VR devices. More specifically, Unity offers two distinct software products: Create Solutions and Operate Solutions.\nCreate Solutions is a subscription-based product, providing developers with tools to create, edit, and run content across Windows, Mac, iOS, Android, and major gaming consoles. And Operate Solutions is a revenue-sharing product, enabling developers to monetize content through digital ads and in-app purchases. Collectively, these two products allow Unity to generate recurring revenue, and grow alongside its clients.\nLast year, an average of 2.7 billion monthly active users engaged with content that was created or operated with Unity, up 63% from 2019. And applications built on Unity averaged 5 billion downloads per month, up 41%. In short, Unity has achieved incredible scale -- and the company is still growing quickly.\n\n\n\nMetric\nQ2 2018 (TTM)\nQ2 2021 (TTM)\nCAGR\n\n\n\n\nRevenue\n$464.5 million\n$929.5 million\n26%\n\n\n\nData source: Unity SEC filings, Ycharts. TTM = trailing-12-months. CAGR = compound annual growth rate.\nGoing forward, Unity still has plenty of room to grow its business. Of course, its platform is a natural fit for game developers -- 94 out of the top 100 game studios are Unity customers -- but the company is also gaining traction in industries like architecture and filmmaking. And during the most recent quarter, Unity added three new automakers, an eyewear retailer, and an appliance manufacturer to its list of clients.\nCurrently, management puts its market opportunity at $29 billion, but that number is expected to climb as new opportunities arise across gaming, AR/VR, and other industries. That's why this growth stock looks like a smart investment.","news_type":1},"isVote":1,"tweetType":1,"viewCount":372,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":838389583,"gmtCreate":1629374211142,"gmtModify":1676530019487,"author":{"id":"3582010429782765","authorId":"3582010429782765","name":"jacq","avatar":"https://static.tigerbbs.com/094ef2aec6c11cb7d041045295e79e0a","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582010429782765","authorIdStr":"3582010429782765"},"themes":[],"htmlText":"Can take a look&nbsp;","listText":"Can take a look&nbsp;","text":"Can take a look","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/838389583","repostId":"2160765013","repostType":4,"repost":{"id":"2160765013","pubTimestamp":1629373500,"share":"https://ttm.financial/m/news/2160765013?lang=&edition=fundamental","pubTime":"2021-08-19 19:45","market":"us","language":"en","title":"Surprise! Here's the Cheapest COVID Vaccine Stock on the Market Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2160765013","media":"Motley Fool","summary":"The least expensive COVID-19 vaccine stock right now isn't one of the leaders in the market -- at least not yet.","content":"<p>Valuation, schmaluation. That seems to be the view of many investors right now when it comes to <b>Moderna</b> (NASDAQ:MRNA). The vaccine maker's market cap is close to $150 billion, and approached $200 billion just a few days ago.</p>\n<p>However, not all vaccine stocks are priced so richly as Moderna. What's the cheapest COVID-19 vaccine stock on the market right now? There's <a href=\"https://laohu8.com/S/AONE.U\">one</a> surprising winner.</p>\n<p><img src=\"https://static.tigerbbs.com/afc8ec91516cee88af3be9e9d44737bf\" tg-width=\"700\" tg-height=\"393\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>A surprising winner</h3>\n<p>There are five companies trading on major U.S. stock exchanges that currently have COVID-19 vaccines on the market somewhere in the world. They include Moderna, <b>Pfizer</b> (NYSE:PFE) and <b>BioNTech</b> (NASDAQ:BNTX), and <b>Johnson &amp; Johnson</b> (NYSE:JNJ), all of which have coronavirus vaccines currently available in the U.S. <b>AstraZeneca</b> (NASDAQ:AZN), which has a vaccine authorized in several countries outside the U.S., is also traded on a U.S. exchange.</p>\n<p>In addition, there are a handful of other publicly traded companies that are evaluating COVID-19 vaccine candidates in late-stage clinical studies. <b>Novavax</b> (NASDAQ:NVAX) expects to file for Emergency Use Authorization (EUA) for its candidate, NVX-CoV2373, later this year. Others include big pharma companies <b>GlaxoSmithKline</b> (NYSE:GSK) and <b><a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a></b> (NASDAQ:SNY), along with the smaller biotechs <b>CureVac</b> (NASDAQ:CVAC) and <b>Dynavax</b> (NASDAQ:DVAX).</p>\n<p>We can't use earnings-based metrics to compare the valuations of these vaccine stocks for a simple reason: Several of them aren't yet profitable. However, to get a good sense of how the stocks stack up against each other, we can use forward price-to-sales (P/S) multiples. I used the current prices and the consensus analyst estimates of 2022 revenue for each stock to determine the cheapest of the bunch:</p>\n<table>\n <thead>\n  <tr>\n   <th>Stock</th>\n   <th><p><b>Forward P/S</b></p></th>\n  </tr>\n </thead>\n <tbody>\n  <tr>\n   <td>GlaxoSmithKline</td>\n   <td>2.1</td>\n  </tr>\n  <tr>\n   <td>Sanofi</td>\n   <td>2.7</td>\n  </tr>\n  <tr>\n   <td>Dynavax</td>\n   <td>2.8</td>\n  </tr>\n  <tr>\n   <td>Novavax</td>\n   <td>3.5</td>\n  </tr>\n  <tr>\n   <td>Pfizer</td>\n   <td>4.1</td>\n  </tr>\n  <tr>\n   <td>AstraZeneca</td>\n   <td>4.3</td>\n  </tr>\n  <tr>\n   <td>Johnson &amp; Johnson</td>\n   <td>4.7</td>\n  </tr>\n  <tr>\n   <td>BioNTech</td>\n   <td>6.4</td>\n  </tr>\n  <tr>\n   <td>CureVac</td>\n   <td>6.7</td>\n  </tr>\n  <tr>\n   <td>Moderna</td>\n   <td>8.5</td>\n  </tr>\n </tbody>\n</table>\n<p>Data source: Yahoo! Finance. Calculations by author.</p>\n<p>GlaxoSmithKline was easily the least expensive vaccine stock of all, based on forward P/S ratios. The big drugmaker isn't as frequently mentioned in discussions about COVID-19 vaccines because it wasn't one of the first to advance a program into clinical testing.</p>\n<p>However, GSK's adjuvant technology is being used in several COVID-19 vaccine candidates, and three of those are currently in late-stage testing.</p>\n<h3>Cheap for a reason, but maybe just a season</h3>\n<p>There's a good reason why GlaxoSmithKline stock is cheap: The company has underperformed compared to its peers. GSK projects that its adjusted earnings per share will fall this year by a \"mid-to-high single-digit percentage.\"</p>\n<p>GlaxoSmithKline CFO Iain Mackay noted in the company's Q2 conference call that the earnings guidance excludes any potential contribution from its COVID-19 programs. The drugmaker posted solid second-quarter results. However, Mackay said, \"There remains potential for further pandemic disruption, and we believe it's premature to change guidance.\"</p>\n<p>Still, there's a case to be made that GSK stock won't be as cheap as it currently is for too much longer. The anticipated spinoff of the company's consumer health unit next year will give GSK around $11 billion to invest in its core pharmaceutical and vaccine business. The company also expects a strong sales rebound for its shingles vaccine Shingrix in 2022.</p>\n<h3>Better bargains</h3>\n<p>There are two vaccine stocks that I think could be better bargains than GlaxoSmithKline -- Dynavax and Novavax. Sure, they both have higher forward P/S multiples than GSK, but they should also have stronger growth prospects.</p>\n<p>Everything seems to be going Dynavax's way these days. In the second quarter, the company reported record sales for its hepatitis B vaccine Heplisav-B, and the vaccine appears to be on track to become the standard of care in the U.S. I expect a solid European launch for Heplisav-B as well.</p>\n<p>Dynavax also has a major growth driver with its CpG 1018 adjuvant. Several companies are developing COVID-19 vaccines using the powerful adjuvant, which is also used in Heplisav-B.</p>\n<p>I think that Novavax is another stock with plenty of room to run. The key for the company is to win EUAs for NVX-CoV2373. Although the vaccine has experienced delays in its EUA submissions, its phase 3 data should be enough to win regulatory green lights, as long as the company can show that it can manufacture it with consistent quality.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Surprise! Here's the Cheapest COVID Vaccine Stock on the Market Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSurprise! Here's the Cheapest COVID Vaccine Stock on the Market Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-19 19:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/19/the-cheapest-covid-vaccine-stock-on-the-market-rig/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Valuation, schmaluation. That seems to be the view of many investors right now when it comes to Moderna (NASDAQ:MRNA). The vaccine maker's market cap is close to $150 billion, and approached $200 ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/19/the-cheapest-covid-vaccine-stock-on-the-market-rig/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/08/19/the-cheapest-covid-vaccine-stock-on-the-market-rig/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2160765013","content_text":"Valuation, schmaluation. That seems to be the view of many investors right now when it comes to Moderna (NASDAQ:MRNA). The vaccine maker's market cap is close to $150 billion, and approached $200 billion just a few days ago.\nHowever, not all vaccine stocks are priced so richly as Moderna. What's the cheapest COVID-19 vaccine stock on the market right now? There's one surprising winner.\n\nImage source: Getty Images.\nA surprising winner\nThere are five companies trading on major U.S. stock exchanges that currently have COVID-19 vaccines on the market somewhere in the world. They include Moderna, Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX), and Johnson & Johnson (NYSE:JNJ), all of which have coronavirus vaccines currently available in the U.S. AstraZeneca (NASDAQ:AZN), which has a vaccine authorized in several countries outside the U.S., is also traded on a U.S. exchange.\nIn addition, there are a handful of other publicly traded companies that are evaluating COVID-19 vaccine candidates in late-stage clinical studies. Novavax (NASDAQ:NVAX) expects to file for Emergency Use Authorization (EUA) for its candidate, NVX-CoV2373, later this year. Others include big pharma companies GlaxoSmithKline (NYSE:GSK) and Sanofi (NASDAQ:SNY), along with the smaller biotechs CureVac (NASDAQ:CVAC) and Dynavax (NASDAQ:DVAX).\nWe can't use earnings-based metrics to compare the valuations of these vaccine stocks for a simple reason: Several of them aren't yet profitable. However, to get a good sense of how the stocks stack up against each other, we can use forward price-to-sales (P/S) multiples. I used the current prices and the consensus analyst estimates of 2022 revenue for each stock to determine the cheapest of the bunch:\n\n\n\nStock\nForward P/S\n\n\n\n\nGlaxoSmithKline\n2.1\n\n\nSanofi\n2.7\n\n\nDynavax\n2.8\n\n\nNovavax\n3.5\n\n\nPfizer\n4.1\n\n\nAstraZeneca\n4.3\n\n\nJohnson & Johnson\n4.7\n\n\nBioNTech\n6.4\n\n\nCureVac\n6.7\n\n\nModerna\n8.5\n\n\n\nData source: Yahoo! Finance. Calculations by author.\nGlaxoSmithKline was easily the least expensive vaccine stock of all, based on forward P/S ratios. The big drugmaker isn't as frequently mentioned in discussions about COVID-19 vaccines because it wasn't one of the first to advance a program into clinical testing.\nHowever, GSK's adjuvant technology is being used in several COVID-19 vaccine candidates, and three of those are currently in late-stage testing.\nCheap for a reason, but maybe just a season\nThere's a good reason why GlaxoSmithKline stock is cheap: The company has underperformed compared to its peers. GSK projects that its adjusted earnings per share will fall this year by a \"mid-to-high single-digit percentage.\"\nGlaxoSmithKline CFO Iain Mackay noted in the company's Q2 conference call that the earnings guidance excludes any potential contribution from its COVID-19 programs. The drugmaker posted solid second-quarter results. However, Mackay said, \"There remains potential for further pandemic disruption, and we believe it's premature to change guidance.\"\nStill, there's a case to be made that GSK stock won't be as cheap as it currently is for too much longer. The anticipated spinoff of the company's consumer health unit next year will give GSK around $11 billion to invest in its core pharmaceutical and vaccine business. The company also expects a strong sales rebound for its shingles vaccine Shingrix in 2022.\nBetter bargains\nThere are two vaccine stocks that I think could be better bargains than GlaxoSmithKline -- Dynavax and Novavax. Sure, they both have higher forward P/S multiples than GSK, but they should also have stronger growth prospects.\nEverything seems to be going Dynavax's way these days. In the second quarter, the company reported record sales for its hepatitis B vaccine Heplisav-B, and the vaccine appears to be on track to become the standard of care in the U.S. I expect a solid European launch for Heplisav-B as well.\nDynavax also has a major growth driver with its CpG 1018 adjuvant. Several companies are developing COVID-19 vaccines using the powerful adjuvant, which is also used in Heplisav-B.\nI think that Novavax is another stock with plenty of room to run. The key for the company is to win EUAs for NVX-CoV2373. Although the vaccine has experienced delays in its EUA submissions, its phase 3 data should be enough to win regulatory green lights, as long as the company can show that it can manufacture it with consistent quality.","news_type":1},"isVote":1,"tweetType":1,"viewCount":118,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":811223241,"gmtCreate":1630328117483,"gmtModify":1676530269938,"author":{"id":"3582010429782765","authorId":"3582010429782765","name":"jacq","avatar":"https://static.tigerbbs.com/094ef2aec6c11cb7d041045295e79e0a","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582010429782765","authorIdStr":"3582010429782765"},"themes":[],"htmlText":"To the moon","listText":"To the moon","text":"To the moon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/811223241","repostId":"1199138618","repostType":4,"isVote":1,"tweetType":1,"viewCount":256,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":832134649,"gmtCreate":1629597728081,"gmtModify":1676530075663,"author":{"id":"3582010429782765","authorId":"3582010429782765","name":"jacq","avatar":"https://static.tigerbbs.com/094ef2aec6c11cb7d041045295e79e0a","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582010429782765","authorIdStr":"3582010429782765"},"themes":[],"htmlText":"Wonder when it can come down before entering&nbsp;","listText":"Wonder when it can come down before entering&nbsp;","text":"Wonder when it can come down before entering","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/832134649","repostId":"2161745814","repostType":4,"repost":{"id":"2161745814","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1629493200,"share":"https://ttm.financial/m/news/2161745814?lang=&edition=fundamental","pubTime":"2021-08-21 05:00","market":"us","language":"en","title":"S&P 500 hasn't fallen 5% from a peak in nearly 200 sessions--what that tells market historians","url":"https://stock-news.laohu8.com/highlight/detail?id=2161745814","media":"Dow Jones","summary":"It is an unbearable lightness of being for the S&P 500 index.\nThe broad-market measure of a basket o","content":"<p>It is an unbearable lightness of being for the S&amp;P 500 index.</p>\n<p>The broad-market measure of a basket of 500 U.S. stocks has been preternaturally resistant to pullbacks of late, despite concerns about the spread of the highly transmissible delta variant of COVID-19 and worries that the Federal Reserve’s strategy to reduce its bond purchases may be ill-timed.</p>\n<p>Yet, the S&amp;P 500 indexSPX,+0.81%has seen a largely uninterrupted ascent to such a degree that Friday marked the 200th session without a drawdown of 5% or more from a recent peak, making the current stretch of levitation the longest such since 2016, when the market went 404 sessions without falling by at least 5% peak to trough.</p>\n<p><img src=\"https://static.tigerbbs.com/d5d7a23827730d58001a0b40420acd79\" tg-width=\"981\" tg-height=\"437\" width=\"100%\" height=\"auto\">It is extremely rare for the market to enjoy such a period of relative effervescence. Indeed, such lengthy stretches without a 5% pullback or better have occurred on only eight occasions in the S&amp;P 500 index, the attached table shows.</p>\n<p>There clearly are reasons why the market is clambering higher in the recovery from COVID, set againsta daunting wall of worry. Investors are jockeying between areas of the market that are expected to boost revenue and profit faster than the rest of the pack and those that are beaten down and might benefit from a fuller economic rebound from coronavirus.</p>\n<p>Buying on Monday helped the Dow Jones Industrial AverageDJIA,+0.65%and the S&amp;P 500 indexSPX,+0.81%produce their 35th and 49th record all-time closing highs of 2021, respectively. Meanwhile, the Nasdaq Composite IndexCOMP,+1.19%stands a little over 2.5% from its record high put in on Aug. 5.</p>\n<p>There is, of course, a sense that the party for stocks can’t last forever.</p>\n<p>So, how does the market tend to perform in period after such a protracted bullish run?</p>\n<p>The data set is very small but the S&amp;P 500 has mostly climbed on a median basis, falling 1.2% in the following year but producing a median gain of 17.6% in a two-year period and 55% in the ensuing five-year period. The mean average return is better, showing a gain of 6.5%, 27.4% and 64%, respectively.</p>\n<p><img src=\"https://static.tigerbbs.com/d556c67fc01e330a57abb4c65802c29d\" tg-width=\"964\" tg-height=\"626\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>S&P 500 hasn't fallen 5% from a peak in nearly 200 sessions--what that tells market historians</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nS&P 500 hasn't fallen 5% from a peak in nearly 200 sessions--what that tells market historians\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-08-21 05:00</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>It is an unbearable lightness of being for the S&amp;P 500 index.</p>\n<p>The broad-market measure of a basket of 500 U.S. stocks has been preternaturally resistant to pullbacks of late, despite concerns about the spread of the highly transmissible delta variant of COVID-19 and worries that the Federal Reserve’s strategy to reduce its bond purchases may be ill-timed.</p>\n<p>Yet, the S&amp;P 500 indexSPX,+0.81%has seen a largely uninterrupted ascent to such a degree that Friday marked the 200th session without a drawdown of 5% or more from a recent peak, making the current stretch of levitation the longest such since 2016, when the market went 404 sessions without falling by at least 5% peak to trough.</p>\n<p><img src=\"https://static.tigerbbs.com/d5d7a23827730d58001a0b40420acd79\" tg-width=\"981\" tg-height=\"437\" width=\"100%\" height=\"auto\">It is extremely rare for the market to enjoy such a period of relative effervescence. Indeed, such lengthy stretches without a 5% pullback or better have occurred on only eight occasions in the S&amp;P 500 index, the attached table shows.</p>\n<p>There clearly are reasons why the market is clambering higher in the recovery from COVID, set againsta daunting wall of worry. Investors are jockeying between areas of the market that are expected to boost revenue and profit faster than the rest of the pack and those that are beaten down and might benefit from a fuller economic rebound from coronavirus.</p>\n<p>Buying on Monday helped the Dow Jones Industrial AverageDJIA,+0.65%and the S&amp;P 500 indexSPX,+0.81%produce their 35th and 49th record all-time closing highs of 2021, respectively. Meanwhile, the Nasdaq Composite IndexCOMP,+1.19%stands a little over 2.5% from its record high put in on Aug. 5.</p>\n<p>There is, of course, a sense that the party for stocks can’t last forever.</p>\n<p>So, how does the market tend to perform in period after such a protracted bullish run?</p>\n<p>The data set is very small but the S&amp;P 500 has mostly climbed on a median basis, falling 1.2% in the following year but producing a median gain of 17.6% in a two-year period and 55% in the ensuing five-year period. The mean average return is better, showing a gain of 6.5%, 27.4% and 64%, respectively.</p>\n<p><img src=\"https://static.tigerbbs.com/d556c67fc01e330a57abb4c65802c29d\" tg-width=\"964\" tg-height=\"626\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"161125":"标普500","513500":"标普500ETF","OEF":"标普100指数ETF-iShares","SPXU":"三倍做空标普500ETF","SDS":"两倍做空标普500ETF","UPRO":"三倍做多标普500ETF","IVV":"标普500指数ETF","OEX":"标普100",".SPX":"S&P 500 Index","SSO":"两倍做多标普500ETF","SH":"标普500反向ETF","SPY":"标普500ETF"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2161745814","content_text":"It is an unbearable lightness of being for the S&P 500 index.\nThe broad-market measure of a basket of 500 U.S. stocks has been preternaturally resistant to pullbacks of late, despite concerns about the spread of the highly transmissible delta variant of COVID-19 and worries that the Federal Reserve’s strategy to reduce its bond purchases may be ill-timed.\nYet, the S&P 500 indexSPX,+0.81%has seen a largely uninterrupted ascent to such a degree that Friday marked the 200th session without a drawdown of 5% or more from a recent peak, making the current stretch of levitation the longest such since 2016, when the market went 404 sessions without falling by at least 5% peak to trough.\nIt is extremely rare for the market to enjoy such a period of relative effervescence. Indeed, such lengthy stretches without a 5% pullback or better have occurred on only eight occasions in the S&P 500 index, the attached table shows.\nThere clearly are reasons why the market is clambering higher in the recovery from COVID, set againsta daunting wall of worry. Investors are jockeying between areas of the market that are expected to boost revenue and profit faster than the rest of the pack and those that are beaten down and might benefit from a fuller economic rebound from coronavirus.\nBuying on Monday helped the Dow Jones Industrial AverageDJIA,+0.65%and the S&P 500 indexSPX,+0.81%produce their 35th and 49th record all-time closing highs of 2021, respectively. Meanwhile, the Nasdaq Composite IndexCOMP,+1.19%stands a little over 2.5% from its record high put in on Aug. 5.\nThere is, of course, a sense that the party for stocks can’t last forever.\nSo, how does the market tend to perform in period after such a protracted bullish run?\nThe data set is very small but the S&P 500 has mostly climbed on a median basis, falling 1.2% in the following year but producing a median gain of 17.6% in a two-year period and 55% in the ensuing five-year period. The mean average return is better, showing a gain of 6.5%, 27.4% and 64%, respectively.","news_type":1},"isVote":1,"tweetType":1,"viewCount":115,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":838389814,"gmtCreate":1629374191738,"gmtModify":1676530019518,"author":{"id":"3582010429782765","authorId":"3582010429782765","name":"jacq","avatar":"https://static.tigerbbs.com/094ef2aec6c11cb7d041045295e79e0a","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582010429782765","authorIdStr":"3582010429782765"},"themes":[],"htmlText":"Can take a look&nbsp;","listText":"Can take a look&nbsp;","text":"Can take a look","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/838389814","repostId":"2160765013","repostType":4,"repost":{"id":"2160765013","pubTimestamp":1629373500,"share":"https://ttm.financial/m/news/2160765013?lang=&edition=fundamental","pubTime":"2021-08-19 19:45","market":"us","language":"en","title":"Surprise! Here's the Cheapest COVID Vaccine Stock on the Market Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2160765013","media":"Motley Fool","summary":"The least expensive COVID-19 vaccine stock right now isn't one of the leaders in the market -- at least not yet.","content":"<p>Valuation, schmaluation. That seems to be the view of many investors right now when it comes to <b>Moderna</b> (NASDAQ:MRNA). The vaccine maker's market cap is close to $150 billion, and approached $200 billion just a few days ago.</p>\n<p>However, not all vaccine stocks are priced so richly as Moderna. What's the cheapest COVID-19 vaccine stock on the market right now? There's <a href=\"https://laohu8.com/S/AONE.U\">one</a> surprising winner.</p>\n<p><img src=\"https://static.tigerbbs.com/afc8ec91516cee88af3be9e9d44737bf\" tg-width=\"700\" tg-height=\"393\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>A surprising winner</h3>\n<p>There are five companies trading on major U.S. stock exchanges that currently have COVID-19 vaccines on the market somewhere in the world. They include Moderna, <b>Pfizer</b> (NYSE:PFE) and <b>BioNTech</b> (NASDAQ:BNTX), and <b>Johnson &amp; Johnson</b> (NYSE:JNJ), all of which have coronavirus vaccines currently available in the U.S. <b>AstraZeneca</b> (NASDAQ:AZN), which has a vaccine authorized in several countries outside the U.S., is also traded on a U.S. exchange.</p>\n<p>In addition, there are a handful of other publicly traded companies that are evaluating COVID-19 vaccine candidates in late-stage clinical studies. <b>Novavax</b> (NASDAQ:NVAX) expects to file for Emergency Use Authorization (EUA) for its candidate, NVX-CoV2373, later this year. Others include big pharma companies <b>GlaxoSmithKline</b> (NYSE:GSK) and <b><a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a></b> (NASDAQ:SNY), along with the smaller biotechs <b>CureVac</b> (NASDAQ:CVAC) and <b>Dynavax</b> (NASDAQ:DVAX).</p>\n<p>We can't use earnings-based metrics to compare the valuations of these vaccine stocks for a simple reason: Several of them aren't yet profitable. However, to get a good sense of how the stocks stack up against each other, we can use forward price-to-sales (P/S) multiples. I used the current prices and the consensus analyst estimates of 2022 revenue for each stock to determine the cheapest of the bunch:</p>\n<table>\n <thead>\n  <tr>\n   <th>Stock</th>\n   <th><p><b>Forward P/S</b></p></th>\n  </tr>\n </thead>\n <tbody>\n  <tr>\n   <td>GlaxoSmithKline</td>\n   <td>2.1</td>\n  </tr>\n  <tr>\n   <td>Sanofi</td>\n   <td>2.7</td>\n  </tr>\n  <tr>\n   <td>Dynavax</td>\n   <td>2.8</td>\n  </tr>\n  <tr>\n   <td>Novavax</td>\n   <td>3.5</td>\n  </tr>\n  <tr>\n   <td>Pfizer</td>\n   <td>4.1</td>\n  </tr>\n  <tr>\n   <td>AstraZeneca</td>\n   <td>4.3</td>\n  </tr>\n  <tr>\n   <td>Johnson &amp; Johnson</td>\n   <td>4.7</td>\n  </tr>\n  <tr>\n   <td>BioNTech</td>\n   <td>6.4</td>\n  </tr>\n  <tr>\n   <td>CureVac</td>\n   <td>6.7</td>\n  </tr>\n  <tr>\n   <td>Moderna</td>\n   <td>8.5</td>\n  </tr>\n </tbody>\n</table>\n<p>Data source: Yahoo! Finance. Calculations by author.</p>\n<p>GlaxoSmithKline was easily the least expensive vaccine stock of all, based on forward P/S ratios. The big drugmaker isn't as frequently mentioned in discussions about COVID-19 vaccines because it wasn't one of the first to advance a program into clinical testing.</p>\n<p>However, GSK's adjuvant technology is being used in several COVID-19 vaccine candidates, and three of those are currently in late-stage testing.</p>\n<h3>Cheap for a reason, but maybe just a season</h3>\n<p>There's a good reason why GlaxoSmithKline stock is cheap: The company has underperformed compared to its peers. GSK projects that its adjusted earnings per share will fall this year by a \"mid-to-high single-digit percentage.\"</p>\n<p>GlaxoSmithKline CFO Iain Mackay noted in the company's Q2 conference call that the earnings guidance excludes any potential contribution from its COVID-19 programs. The drugmaker posted solid second-quarter results. However, Mackay said, \"There remains potential for further pandemic disruption, and we believe it's premature to change guidance.\"</p>\n<p>Still, there's a case to be made that GSK stock won't be as cheap as it currently is for too much longer. The anticipated spinoff of the company's consumer health unit next year will give GSK around $11 billion to invest in its core pharmaceutical and vaccine business. The company also expects a strong sales rebound for its shingles vaccine Shingrix in 2022.</p>\n<h3>Better bargains</h3>\n<p>There are two vaccine stocks that I think could be better bargains than GlaxoSmithKline -- Dynavax and Novavax. Sure, they both have higher forward P/S multiples than GSK, but they should also have stronger growth prospects.</p>\n<p>Everything seems to be going Dynavax's way these days. In the second quarter, the company reported record sales for its hepatitis B vaccine Heplisav-B, and the vaccine appears to be on track to become the standard of care in the U.S. I expect a solid European launch for Heplisav-B as well.</p>\n<p>Dynavax also has a major growth driver with its CpG 1018 adjuvant. Several companies are developing COVID-19 vaccines using the powerful adjuvant, which is also used in Heplisav-B.</p>\n<p>I think that Novavax is another stock with plenty of room to run. The key for the company is to win EUAs for NVX-CoV2373. Although the vaccine has experienced delays in its EUA submissions, its phase 3 data should be enough to win regulatory green lights, as long as the company can show that it can manufacture it with consistent quality.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Surprise! Here's the Cheapest COVID Vaccine Stock on the Market Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSurprise! Here's the Cheapest COVID Vaccine Stock on the Market Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-19 19:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/19/the-cheapest-covid-vaccine-stock-on-the-market-rig/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Valuation, schmaluation. That seems to be the view of many investors right now when it comes to Moderna (NASDAQ:MRNA). The vaccine maker's market cap is close to $150 billion, and approached $200 ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/19/the-cheapest-covid-vaccine-stock-on-the-market-rig/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/08/19/the-cheapest-covid-vaccine-stock-on-the-market-rig/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2160765013","content_text":"Valuation, schmaluation. That seems to be the view of many investors right now when it comes to Moderna (NASDAQ:MRNA). The vaccine maker's market cap is close to $150 billion, and approached $200 billion just a few days ago.\nHowever, not all vaccine stocks are priced so richly as Moderna. What's the cheapest COVID-19 vaccine stock on the market right now? There's one surprising winner.\n\nImage source: Getty Images.\nA surprising winner\nThere are five companies trading on major U.S. stock exchanges that currently have COVID-19 vaccines on the market somewhere in the world. They include Moderna, Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX), and Johnson & Johnson (NYSE:JNJ), all of which have coronavirus vaccines currently available in the U.S. AstraZeneca (NASDAQ:AZN), which has a vaccine authorized in several countries outside the U.S., is also traded on a U.S. exchange.\nIn addition, there are a handful of other publicly traded companies that are evaluating COVID-19 vaccine candidates in late-stage clinical studies. Novavax (NASDAQ:NVAX) expects to file for Emergency Use Authorization (EUA) for its candidate, NVX-CoV2373, later this year. Others include big pharma companies GlaxoSmithKline (NYSE:GSK) and Sanofi (NASDAQ:SNY), along with the smaller biotechs CureVac (NASDAQ:CVAC) and Dynavax (NASDAQ:DVAX).\nWe can't use earnings-based metrics to compare the valuations of these vaccine stocks for a simple reason: Several of them aren't yet profitable. However, to get a good sense of how the stocks stack up against each other, we can use forward price-to-sales (P/S) multiples. I used the current prices and the consensus analyst estimates of 2022 revenue for each stock to determine the cheapest of the bunch:\n\n\n\nStock\nForward P/S\n\n\n\n\nGlaxoSmithKline\n2.1\n\n\nSanofi\n2.7\n\n\nDynavax\n2.8\n\n\nNovavax\n3.5\n\n\nPfizer\n4.1\n\n\nAstraZeneca\n4.3\n\n\nJohnson & Johnson\n4.7\n\n\nBioNTech\n6.4\n\n\nCureVac\n6.7\n\n\nModerna\n8.5\n\n\n\nData source: Yahoo! Finance. Calculations by author.\nGlaxoSmithKline was easily the least expensive vaccine stock of all, based on forward P/S ratios. The big drugmaker isn't as frequently mentioned in discussions about COVID-19 vaccines because it wasn't one of the first to advance a program into clinical testing.\nHowever, GSK's adjuvant technology is being used in several COVID-19 vaccine candidates, and three of those are currently in late-stage testing.\nCheap for a reason, but maybe just a season\nThere's a good reason why GlaxoSmithKline stock is cheap: The company has underperformed compared to its peers. GSK projects that its adjusted earnings per share will fall this year by a \"mid-to-high single-digit percentage.\"\nGlaxoSmithKline CFO Iain Mackay noted in the company's Q2 conference call that the earnings guidance excludes any potential contribution from its COVID-19 programs. The drugmaker posted solid second-quarter results. However, Mackay said, \"There remains potential for further pandemic disruption, and we believe it's premature to change guidance.\"\nStill, there's a case to be made that GSK stock won't be as cheap as it currently is for too much longer. The anticipated spinoff of the company's consumer health unit next year will give GSK around $11 billion to invest in its core pharmaceutical and vaccine business. The company also expects a strong sales rebound for its shingles vaccine Shingrix in 2022.\nBetter bargains\nThere are two vaccine stocks that I think could be better bargains than GlaxoSmithKline -- Dynavax and Novavax. Sure, they both have higher forward P/S multiples than GSK, but they should also have stronger growth prospects.\nEverything seems to be going Dynavax's way these days. In the second quarter, the company reported record sales for its hepatitis B vaccine Heplisav-B, and the vaccine appears to be on track to become the standard of care in the U.S. I expect a solid European launch for Heplisav-B as well.\nDynavax also has a major growth driver with its CpG 1018 adjuvant. Several companies are developing COVID-19 vaccines using the powerful adjuvant, which is also used in Heplisav-B.\nI think that Novavax is another stock with plenty of room to run. The key for the company is to win EUAs for NVX-CoV2373. Although the vaccine has experienced delays in its EUA submissions, its phase 3 data should be enough to win regulatory green lights, as long as the company can show that it can manufacture it with consistent quality.","news_type":1},"isVote":1,"tweetType":1,"viewCount":213,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":834549909,"gmtCreate":1629815431601,"gmtModify":1676530140737,"author":{"id":"3582010429782765","authorId":"3582010429782765","name":"jacq","avatar":"https://static.tigerbbs.com/094ef2aec6c11cb7d041045295e79e0a","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582010429782765","authorIdStr":"3582010429782765"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/834549909","repostId":"1191163975","repostType":4,"repost":{"id":"1191163975","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1629814313,"share":"https://ttm.financial/m/news/1191163975?lang=&edition=fundamental","pubTime":"2021-08-24 22:11","market":"us","language":"en","title":"Oil up 2% on brighter demand outlook and Mexican outage","url":"https://stock-news.laohu8.com/highlight/detail?id=1191163975","media":"Reuters","summary":"LONDON, Aug 24 (Reuters) - Oil prices rose on Tuesday, extending sharp gains on a bullish demand out","content":"<p>LONDON, Aug 24 (Reuters) - Oil prices rose on Tuesday, extending sharp gains on a bullish demand outlook as U.S. regulators issued their first full approval for a COVID-19 vaccine and Mexico suffered a large production outage.</p>\n<p>Brent crude oil futures were up $1.50, or 2.2%, at $70.25 a barrel by 13442 GMT while U.S. West Texas Intermediate (WTI) gained $1.34, or 2%, to $66.98.</p>\n<p>Both benchmarks jumped more than 5% on Monday, helped by a weaker dollar, after marking their biggest weekly losses in more than nine months last week.</p>\n<p>Though a resurgent pandemic has fuelled health system concerns, \"economically harmful containment measures seem rather unlikely\", said Julius Baer analyst Norbert Rucker, citing the effectiveness of coronavirus vaccines.</p>\n<p>The U.S. Food and Drug Administration (FDA) on Monday issued full approval for the Pfizer/BioNTech two-dose vaccine, having authorised it for emergency use last December. Health officials hope the action will convince unvaccinated Americans that the shot is safe and effective.</p>\n<p>Analysts said that China's apparent success in fighting the spread of the Delta variant also boosted demand sentiment, with no cases of locally transmitted infections reported in latest data.</p>\n<p>Also supporting oil prices was a fire on an oil platform off Mexico on Sunday. The fire killed five workers and halted 421,000 barrels per day of production, representing about a quarter of the country's overall output.</p>\n<p>The U.S. Department of Energy on Monday said it would sell up to 20 million barrels of crude from the Strategic Petroleum Reserve (SPR) oil stocks to comply with legislation, with deliveries to take place between Oct. 1 and Dec. 15.</p>\n<p>Meanwhile, Indian refiners' crude throughput in July bounced to its highest in three months as fuel demand rebounded and buoyed prices.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Oil up 2% on brighter demand outlook and Mexican outage</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOil up 2% on brighter demand outlook and Mexican outage\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-08-24 22:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>LONDON, Aug 24 (Reuters) - Oil prices rose on Tuesday, extending sharp gains on a bullish demand outlook as U.S. regulators issued their first full approval for a COVID-19 vaccine and Mexico suffered a large production outage.</p>\n<p>Brent crude oil futures were up $1.50, or 2.2%, at $70.25 a barrel by 13442 GMT while U.S. West Texas Intermediate (WTI) gained $1.34, or 2%, to $66.98.</p>\n<p>Both benchmarks jumped more than 5% on Monday, helped by a weaker dollar, after marking their biggest weekly losses in more than nine months last week.</p>\n<p>Though a resurgent pandemic has fuelled health system concerns, \"economically harmful containment measures seem rather unlikely\", said Julius Baer analyst Norbert Rucker, citing the effectiveness of coronavirus vaccines.</p>\n<p>The U.S. Food and Drug Administration (FDA) on Monday issued full approval for the Pfizer/BioNTech two-dose vaccine, having authorised it for emergency use last December. Health officials hope the action will convince unvaccinated Americans that the shot is safe and effective.</p>\n<p>Analysts said that China's apparent success in fighting the spread of the Delta variant also boosted demand sentiment, with no cases of locally transmitted infections reported in latest data.</p>\n<p>Also supporting oil prices was a fire on an oil platform off Mexico on Sunday. The fire killed five workers and halted 421,000 barrels per day of production, representing about a quarter of the country's overall output.</p>\n<p>The U.S. Department of Energy on Monday said it would sell up to 20 million barrels of crude from the Strategic Petroleum Reserve (SPR) oil stocks to comply with legislation, with deliveries to take place between Oct. 1 and Dec. 15.</p>\n<p>Meanwhile, Indian refiners' crude throughput in July bounced to its highest in three months as fuel demand rebounded and buoyed prices.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1191163975","content_text":"LONDON, Aug 24 (Reuters) - Oil prices rose on Tuesday, extending sharp gains on a bullish demand outlook as U.S. regulators issued their first full approval for a COVID-19 vaccine and Mexico suffered a large production outage.\nBrent crude oil futures were up $1.50, or 2.2%, at $70.25 a barrel by 13442 GMT while U.S. West Texas Intermediate (WTI) gained $1.34, or 2%, to $66.98.\nBoth benchmarks jumped more than 5% on Monday, helped by a weaker dollar, after marking their biggest weekly losses in more than nine months last week.\nThough a resurgent pandemic has fuelled health system concerns, \"economically harmful containment measures seem rather unlikely\", said Julius Baer analyst Norbert Rucker, citing the effectiveness of coronavirus vaccines.\nThe U.S. Food and Drug Administration (FDA) on Monday issued full approval for the Pfizer/BioNTech two-dose vaccine, having authorised it for emergency use last December. Health officials hope the action will convince unvaccinated Americans that the shot is safe and effective.\nAnalysts said that China's apparent success in fighting the spread of the Delta variant also boosted demand sentiment, with no cases of locally transmitted infections reported in latest data.\nAlso supporting oil prices was a fire on an oil platform off Mexico on Sunday. The fire killed five workers and halted 421,000 barrels per day of production, representing about a quarter of the country's overall output.\nThe U.S. Department of Energy on Monday said it would sell up to 20 million barrels of crude from the Strategic Petroleum Reserve (SPR) oil stocks to comply with legislation, with deliveries to take place between Oct. 1 and Dec. 15.\nMeanwhile, Indian refiners' crude throughput in July bounced to its highest in three months as fuel demand rebounded and buoyed prices.","news_type":1},"isVote":1,"tweetType":1,"viewCount":212,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":803289054,"gmtCreate":1627441321578,"gmtModify":1703490033060,"author":{"id":"3582010429782765","authorId":"3582010429782765","name":"jacq","avatar":"https://static.tigerbbs.com/094ef2aec6c11cb7d041045295e79e0a","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582010429782765","authorIdStr":"3582010429782765"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/803289054","repostId":"2154432059","repostType":4,"repost":{"id":"2154432059","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1627435733,"share":"https://ttm.financial/m/news/2154432059?lang=&edition=fundamental","pubTime":"2021-07-28 09:28","market":"fut","language":"en","title":"Oil rises on U.S. fuel drawdowns despite surging coronavirus cases","url":"https://stock-news.laohu8.com/highlight/detail?id=2154432059","media":"Reuters","summary":"MELBOURNE, July 28 (Reuters) - Oil prices climbed on Wednesday after industry data showed U.S. crude","content":"<p>MELBOURNE, July 28 (Reuters) - Oil prices climbed on Wednesday after industry data showed U.S. crude and product inventories fell more sharply than expected last week, reinforcing expectations that demand will outstrip supply growth even amid a surge in COVID-19 cases.</p>\n<p>U.S. West Texas Intermediate <a href=\"https://laohu8.com/S/WTI\">$(WTI)$</a> crude futures rose 43 cents, or 0.6%, to $72.08 a barrel at 0119 GMT, reversing Tuesday's 0.4% decline.</p>\n<p>Brent crude futures rose 38 cents, or 0.5%, to $74.86 a barrel, after shedding 2 cents on Tuesday in the first decline in six days.</p>\n<p>Data from the American Petroleum Institute industry group showed U.S. crude stocks fell by 4.7 million barrels for the week ended July 23, gasoline inventories dropped by 6.2 million barrels and distillate stocks were down 1.9 million barrels, according to two market sources, who spoke on condition of anonymity.</p>\n<p>That compared with analysts' expectations for a 2.9 million fall in crude stocks, following a surprise rise in crude inventories the previous week in what was the first increase since May.</p>\n<p>Traders are awaiting data from the U.S. Energy Information Administration <a href=\"https://laohu8.com/S/EIA\">$(EIA)$</a> on Wednesday to confirm the drop in stocks.</p>\n<p>\"Most energy traders were unfazed by last week's build, so expectations should be high for the EIA crude oil inventory data to confirm inventories resumed their declining trend,\" OANDA analyst Edward Moya said in a research note.</p>\n<p>On gasoline stocks, analysts had expected a 900,000 barrel decline drop in the week to July 23.</p>\n<p>\"The U.S. is still in peak driving season and everyone is trying to make the most of this summer,\" Moya said.</p>\n<p>Fuel demand expectations are undented by soaring cases of the highly infectious Delta variant of the coronavirus in the United States, where the seven-day average for new cases has risen to 57,126. That is about a quarter of the pandemic peak.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Oil rises on U.S. fuel drawdowns despite surging coronavirus cases</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOil rises on U.S. fuel drawdowns despite surging coronavirus cases\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-07-28 09:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>MELBOURNE, July 28 (Reuters) - Oil prices climbed on Wednesday after industry data showed U.S. crude and product inventories fell more sharply than expected last week, reinforcing expectations that demand will outstrip supply growth even amid a surge in COVID-19 cases.</p>\n<p>U.S. West Texas Intermediate <a href=\"https://laohu8.com/S/WTI\">$(WTI)$</a> crude futures rose 43 cents, or 0.6%, to $72.08 a barrel at 0119 GMT, reversing Tuesday's 0.4% decline.</p>\n<p>Brent crude futures rose 38 cents, or 0.5%, to $74.86 a barrel, after shedding 2 cents on Tuesday in the first decline in six days.</p>\n<p>Data from the American Petroleum Institute industry group showed U.S. crude stocks fell by 4.7 million barrels for the week ended July 23, gasoline inventories dropped by 6.2 million barrels and distillate stocks were down 1.9 million barrels, according to two market sources, who spoke on condition of anonymity.</p>\n<p>That compared with analysts' expectations for a 2.9 million fall in crude stocks, following a surprise rise in crude inventories the previous week in what was the first increase since May.</p>\n<p>Traders are awaiting data from the U.S. Energy Information Administration <a href=\"https://laohu8.com/S/EIA\">$(EIA)$</a> on Wednesday to confirm the drop in stocks.</p>\n<p>\"Most energy traders were unfazed by last week's build, so expectations should be high for the EIA crude oil inventory data to confirm inventories resumed their declining trend,\" OANDA analyst Edward Moya said in a research note.</p>\n<p>On gasoline stocks, analysts had expected a 900,000 barrel decline drop in the week to July 23.</p>\n<p>\"The U.S. is still in peak driving season and everyone is trying to make the most of this summer,\" Moya said.</p>\n<p>Fuel demand expectations are undented by soaring cases of the highly infectious Delta variant of the coronavirus in the United States, where the seven-day average for new cases has risen to 57,126. That is about a quarter of the pandemic peak.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SCO":"二倍做空彭博原油指数ETF","DUG":"二倍做空石油与天然气ETF(ProShares)","USO":"美国原油ETF","DWT":"三倍做空原油ETN","DDG":"ProShares做空石油与天然气ETF","UCO":"二倍做多彭博原油ETF"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2154432059","content_text":"MELBOURNE, July 28 (Reuters) - Oil prices climbed on Wednesday after industry data showed U.S. crude and product inventories fell more sharply than expected last week, reinforcing expectations that demand will outstrip supply growth even amid a surge in COVID-19 cases.\nU.S. West Texas Intermediate $(WTI)$ crude futures rose 43 cents, or 0.6%, to $72.08 a barrel at 0119 GMT, reversing Tuesday's 0.4% decline.\nBrent crude futures rose 38 cents, or 0.5%, to $74.86 a barrel, after shedding 2 cents on Tuesday in the first decline in six days.\nData from the American Petroleum Institute industry group showed U.S. crude stocks fell by 4.7 million barrels for the week ended July 23, gasoline inventories dropped by 6.2 million barrels and distillate stocks were down 1.9 million barrels, according to two market sources, who spoke on condition of anonymity.\nThat compared with analysts' expectations for a 2.9 million fall in crude stocks, following a surprise rise in crude inventories the previous week in what was the first increase since May.\nTraders are awaiting data from the U.S. Energy Information Administration $(EIA)$ on Wednesday to confirm the drop in stocks.\n\"Most energy traders were unfazed by last week's build, so expectations should be high for the EIA crude oil inventory data to confirm inventories resumed their declining trend,\" OANDA analyst Edward Moya said in a research note.\nOn gasoline stocks, analysts had expected a 900,000 barrel decline drop in the week to July 23.\n\"The U.S. is still in peak driving season and everyone is trying to make the most of this summer,\" Moya said.\nFuel demand expectations are undented by soaring cases of the highly infectious Delta variant of the coronavirus in the United States, where the seven-day average for new cases has risen to 57,126. That is about a quarter of the pandemic peak.","news_type":1},"isVote":1,"tweetType":1,"viewCount":196,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}